The genetic and phenotypic correlates of neonatal Complement Component 3 and 4

protein concentrations with a focus on psychiatric and autoimmune disorders

- 4 Nis Borbye-Lorenzen, PhD*equal first author
- 5 Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institute,
- 6 Copenhagen, Denmark
- 8 Zhihong Zhu, PhD*equal first author
- 9 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 12 Esben Agerbo, DrMedSc
- 13 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 14 Denmark

1 2

3

7

10 11

17

22

28

31

37

42

- 15 Centre for Integrated Register-based Research, Aarhus University, CIRRAU, 8210 Aarhus V, Denmark
- 16 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 18 Clara Albiñana, MSc
- 19 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 20 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 21 Denmark
- 23 Michael E. Benros, MD, PhD
- 24 Copenhagen Research Centre for Mental Health, Mental Health Centre Copenhagen, Copenhagen
- 25 University Hospital, Hellerup, Denmark
- 26 Department of Immunology and Microbiology, Faculty of Health and Medical Sciences,
- 27 University of Copenhagen, Copenhagen, Denmark
- 29 Beilei Bian, MSc
- 30 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
- 32 Anders D Børglum, MD, PhD
- 33 Department of Biomedicine and the iSEQ Center, Aarhus University, Aarhus, Denmark
- 34 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 35 Denmark
- 36 Center for Genomics and Personalized Medicine, CGPM, Aarhus, Denmark
- 38 Cynthia M. Bulik, PhD
- 39 Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, USA
- 40 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 41 Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, USA
- 43 Jean-Christophe Philippe Goldtsche Debost, MD, PhD
- 44 Aarhus University Hospital Skejby, Department of Psychosis, Aarhus Nord, Denmark
- 45 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 47 Jakob Grove, PhD
- 48 Department of Biomedicine (Human Genetics), Aarhus University, Aarhus, Denmark
- 49 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 50 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

51 Center for Genomics and Personalized Medicine, Aarhus, Denmark

- 52 Bioinformatics Research Centre, Aarhus University, 8000 Aarhus C, Denmark
- 54 David M. Hougaard, DMSci
- 55 Department for Congenital Disorders, Statens Serum Institut, 2300 Copenhagen S, Denmark.
- 56 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 57 Denmark

53

58

62

67

73

77

84

87

90

94

- 59 Allan F McRae, PhD
- 60 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072,
- 61 Australia
- 63 Ole Mors, PhD
- 64 Psychosis Research Unit, Aarhus University Hospital Psychiatry, Denmark
- 65 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 66 Denmark
- 68 Preben Bo Mortensen, MD, PhD
- 69 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 70 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 71 Denmark
- 72 Centre for Integrated Register-based Research, Aarhus University, CIRRAU, 8210 Aarhus V, Denmark
- 74 Katherine L. Musliner, PhD
- 75 Department of Affective Disorders, Aarhus University and Aarhus University Hospital-Psychiatry,
- 76 Aarhus Denmark
- 78 Merete Nordentoft, MD, DrMedSc
- 79 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V,
- 80 Denmark
- 81 Mental Health Services in the Capital Region of Denmark, Mental Health Center Copenhagen,
- 82 University of Copenhagen, 2100 Copenhagen, Denmark
- 83 Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen N, Denmark
- 85 Liselotte V. Petersen, PhD.
- 86 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 88 Florian Privé, PhD
- 89 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark
- 91 Julia Sidorenko, PhD
- 92 Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072,
- 93 Australia
- 95 Kristin Skogstrand, PhD
- 96 Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institute,
- 97 Copenhagen, Denmark
- 99 Thomas Werge, PhD
- 100 Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital.
- 101 Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen N, Denmark

102 Lundbeck Center for Geogenetics, GLOBE Institute, University of Copenhagen, Copenhagen, 103 104 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V, 105 Denmark 106 107 Naomi R Wray, PhD Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, 108 109 110 Queensland Brain Institute, The University of Queensland, Brisbane, Queensland 4072, Australia 111 112 113 Bjarni J. Vilhjálmsson, PhD 114 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark 115 Bioinformatics Research Centre, Aarhus University, 8000 Aarhus C, Denmark 116 The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, 8210 Aarhus V, 117 Denmark 118 119 John J. McGrath, MD, PhD 120 National Centre for Register-Based Research, Aarhus University, 8210 Aarhus V, Denmark 121 Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Brisbane, 122 Queensland 4076, Australia 123 Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia 124 125 126

Abstract

127

128 129

130

131

132

133

134

135

136 137

138

139 140

141

142 143

144

145

146

147 148

149

150

151

152

153 154

155

156

157

158

The complement system, including complement components 3 and 4 (C3, C4), traditionally has been linked to innate immunity. More recently, complement components have also been implicated in brain development and the risk of schizophrenia. Based on a large, population-based case-cohort study, we measured the blood concentrations of C3 and C4 in 68,768 neonates. We found a strong correlation between the concentrations of C3 and C4 (phenotypic correlation = 0.65, P-value < 1.0×10^{-100} , genetic correlation = 0.38, P-value = 1.9×10^{-35}). A genome-wide association study (GWAS) for C4 protein concentration identified 36 independent loci, 30 of which were in or near the major histocompatibility complex on chromosome 6 (which includes the C4 gene), while six loci were found on six other chromosomes. A GWAS for C3 identified 15 independent loci, seven of which were located in the C3 gene on chromosome 19, and eight loci on five other chromosomes. We found no association between (a) measured neonatal C3 and C4 concentrations, imputed C4 haplotypes, or predicted C4 gene expression, with (b) schizophrenia (SCZ), bipolar disorder (BIP), depression (DEP), autism spectrum disorder, attention deficit hyperactivity disorder or anorexia nervosa diagnosed in later life. Mendelian randomisation (MR) suggested a small positive association between higher C4 protein concentration and an increased risk of SCZ, BIP, and DEP, but these findings did not persist in more stringent analyses. Evidence from MR supported causal relationships between C4 concentration and several autoimmune disorders: systemic lupus erythematosus (SLE, OR and 95% confidence interval, 0.37, 0.34 - 0.42); type-1 diabetes (T1D, 0.54, 0.50 - 0.58); multiple sclerosis (MS, 0.68, 0.63 - 0.74); rheumatoid arthritis (0.85, 0.80 - 0.91); and Crohn's disease (1.26, 1.19 -1.34). A phenome-wide association study (PheWAS) in UK Biobank confirmed that the genetic correlates of C4 concentration were associated a range of autoimmune disorders including coeliac disease, thyrotoxicosis, hypothyroidism, T1D, sarcoidosis, psoriasis, SLE and ankylosing spondylitis. We found no evidence of associations between C3 versus mental or autoimmune disorders based on either MR or PheWAS. In general, our results do not support the hypothesis that C4 is causally associated with the risk of SCZ (nor several other mental disorders). We provide new evidence to support the hypothesis that higher C4 concentration is associated with lower risks of autoimmune disorders. Keywords: Complement Component, C3, C4, schizophrenia, psychiatric disorders, autoimmune

disorders, genome-wide association study, Mendelian randomization, phenome-wide association study, dried blood spots.

Introduction

The complement systems are an integral part of the innate immune response¹⁻⁴. These

phylogenetically-ancient systems involve complex and interlinked amplification cascades, which can

be triggered to protect the body from pathogens. Elements of the system are also involved in a

range of additional physiological functions. For example, a growing body of evidence links elements

of the complement systems (e.g. Complement Component 4; C4) to brain development and

psychiatric disorders⁵⁻⁷.

autoimmune disorders.

159

160161

162

164165

166

167168

169

170

171

172

173174

175

176

177

178179

180 181

182 183

184

185186

187

188

189 190

191 192

193

194 195

196

197198

199

200

201

202

203

204

Several of the genes that encode components of the complement system, including C4, are located within the major histocompatibility complex (MHC). Linking disease phenotypes with loci within the MHC is difficult because of the long-range linkage disequilibrium (LD) in this region. Furthermore, the C4 gene has two homologous isoforms (C4A and C4B), each of which can vary according to an insertion of a human endogenous retrovirus (HERV) transposon, and which can vary between one to three genocopies per haplotype⁸. Sekar and colleagues⁹ proposed that genetic variants involving the C4 gene could account for the strong signal over this region detected in genome-wide association studies (GWAS) of schizophrenia¹⁰. They found that the expression of mRNA transcripts coding for the C4A-related isoform was increased in post-mortem schizophrenia brain samples (cases = 35, controls = 70), and also reported that the C4A copy number was associated with both increased C4A expression in the brain and increased risk of schizophrenia. These findings are of interest to neurodevelopmental disorders, given evidence that C4 and related members of the complement systems are involved in synaptic pruning during early brain development^{9,11-13}. Apart from the links with schizophrenia, increased C4A copy number has also been associated with a decreased risk of autoimmune disorders^{14,15}. In light of the shared genetic architecture between different types of mental disorders¹⁶, and the links between C4A alleles and risk of autoimmune disorders, there is a

need to explore if the putative risk haplotypes are associated with a wider range of both mental- and

As more copies of the C4A gene are associated with increased expression of C4A-related transcripts in the brain^{9,17}, it is reasonable to assume that an increased copy number of the C4A gene would also be reflected in increased expression of the C4 protein. C4 is an abundant circulating protein, produced mainly in the liver, and evidence from transgenic mouse experiments¹² and human observational studies^{18,19} confirms a dose-response relationship between increased *C4* copy number and increased concentration of C4 protein in the peripheral circulation. The concentration of the C4 protein is correlated with other members of the complement family, including complement component C3 (encoded by the C3 gene)²⁰. A recent systematic review and meta-analysis found that the serum concentrations of C4 and C3 did not differ in those with schizophrenia versus controls²¹. However, the neurodevelopmental hypothesis of schizophrenia suggests that early life disruption of brain development may underpin the subsequent adult-onset disorder^{22,23}. Additional evidence suggests that complement-related synaptic pruning may be most prominent during early life (e.g. C3 protein expression peaks in the early post-natal period and decreases with age)^{7,24}. We are aware of one study that examined neonatal C4 concentration in a schizophrenia case-control study (cases = 75, controls = 644)²⁵. This study found evidence that an increased concentration of one of the two measured peptides within the protein encoded by C4A was associated with an increased risk of subsequent schizophrenia. There is a need to explore the association between complement-related protein concentrations and later mental disorders based on larger samples of neonatal blood samples.

We examined the association between neonatal C3 and C4 concentrations and later health outcomes based on a population-based case-cohort study that had access to archived neonatal dried

blood spots^{26,27}. Building on the only published GWAS of serum complement components C3 and C4 (studies based on 3,495 Han Chinese men¹⁸), we completed GWASs for C3 and C4 neonatal concentrations based on 68,768 samples and estimated the heritability of these phenotypes. We were also able to assess the association between imputed C4 haplotypes and observed neonatal C4 protein concentration. We examined the association of both (a) imputed C4 haplotypes and (b) observed C3 and C4 protein concentration in neonatal dried blood spots versus the risk of a range of clinically observed mental disorders in the case-cohort study (i.e. schizophrenia, bipolar disorder, depression, autism spectrum disorder, attention deficit hyperactivity disorder and anorexia nervosa). Based on the results of the GWASs of C3 and C4, we used: (a) bioinformatics tools to explore gene properties of the genome-wide significant loci (summary-data-based MR [SMR], genebased analyses and gene set analyses); (b) Mendelian randomization analyses to explore the associations between C3 and C4 protein concentrations versus a range of mental disorders (as listed above) and autoimmune disorders (multiple sclerosis [MS], type-1 diabetes [T1D], Crohn's disease [CD], ulcerative colitis [UC], rheumatoid arthritis [RA], and systemic lupus erythematosus [SLE]), and finally, (c) phenome-wide association studies (PheWAS)²⁸ to examine the relationship between the genetic correlates of C3 and C4 protein concentrations versus mental and autoimmune disorders, as well as a wide range of other health phenotypes. A summary of the overall methods is shown in Figure 1.

1. Analyses using individual-level data within the iPSYCH2012 case-cohort study Phenotype descriptive analysis Genotypes **Haplotypes** • Mesoscale quantification of C3 and C4 • QC of genotypes and Imputation with rapid Haplotype imputation imputation for consortias pipeline (RICOPILI) • Associations of haplotypes with protein • Assess phenotype distribution · Heritability, SNP-based heritability concentrations • Adjust for batch effects and apply rank-• Genetic correlation between C3 and C4 Associations of haplotypes with mental based inverse normal transformation • Assess phenotypic correlation • Genome-wide association studies (GWASs) of • Associations of predicted gene expressions C3 and C4 protein concentrations with mental disorders Independent loci by conditional and joint • Associations of protein concentrations with (COJO) analysis mental disorders • GWAS of C4 protein concentration adjusted for genetic variants in the majo histocompatibility complex (MHC) region. 2. Analyses using GWAS summary data from iPSYCH2012 and public data sources Annotation Mendelian randomisation **PheWAS** (UK Biobank phenotypes) (GWAS summary data) (GWAS summary data) Functional mapping and Annotation • Generalised SMR (GSMR) • Phenome-Wide Association Study of Genome-Wide Association - ICD-10 disorders - Neuropsychiatric disorders Studies (FUMA) - Anthropometry & brain imaging - Autoimmune disorders - Gene-based analysis - Infectious disease antigen - Enrichment analysis • Summary-data-based MR (SMR) - GTEx v8, tissues from blood, brain,

Figure 1. Methods figure.

205

206

207208

209210

211212

213

214

215216

217218

219

220221

222

223

224

METHODS

227

228229

230

231232

233

234

235

236

237238

239

240241

242

243

244

245246

247

248

249

250

251

252

253

254

255

256

257258

259

260

261

262

263

264

265266

267

268269

270

271

272

273274

275

276

The iPSYCH2012 study

Key elements of this study were based on the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH) sample²⁶, a population-based case-cohort designed to study the genetic and environmental factors of schizophrenia (SCZ), bipolar disorder (BIP), depression (DEP), autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The original iPSYCH sample (known as iPSYCH2012) included information on case status complete through 31 December 2012. We also included 4,791 anorexia nervosa cases (AN; ANGI-DK) from the Anorexia Nervosa Genetics Initiative (ANGI)²⁹, which had the same design as iPSYCH2012. Henceforth, we refer to iPSYCH2012 as the combined dataset with the ANGI samples. The iPSYCH2012 sample is nested within the entire Danish population born between 1981 and 2005 (n=1,472,762). Diagnoses were identified in the Danish Central Psychiatric Research Register^{30,31}, which includes all inpatient contacts in Danish psychiatric hospitals since 1969 and all outpatient and emergency contacts since 1995. The ICD-10 codes used to classify the psychiatric disorder cases can be found in Supplementary Table 1. The phenotype information for the iPSYCH2012 participants was updated for the target mental disorders until December 2016. The case-cohort sample includes a populationbased random sub-cohort 32 (N = 30,000) with an inclusion probability of 2.04% of the study base (30,000 / 1,472,762). This sub-cohort also includes some participants with the target mental disorders of interest. The genotypes and C3 and C4 protein concentrations were measured in neonatal dried bloodspots (DBSs) taken as part of routine screening at birth from all babies born in Denmark since 1981 and stored in the Danish Neonatal Screening Biobank³³. Dried blood spot samples have been collected from practically all neonates born in Denmark since 1st May 1981 and stored at -20 °C. Samples are collected 4-7 days after birth. After the dried blood spots were retrieved from the biobank, samples were extracted in a PBS buffer and stored for further use at -80°C. Subsequently, DNA was extracted according to previously published methods³⁴. After storage the protein extracts were assayed for C3 and C4 concentrations. Thus, all genotypes and C3/C4 protein concentration data originated from a single DBS extraction. Additional details related to blood spot extraction and storage are provided in **Supplementary Methods 1**.

Ethical framework

Material from the Danish Neonatal Screening Biobank has been used primarily for screening for congenital disorders, but are also stored for follow-up diagnostics, screening, quality control and research. According to Danish legislation, material from The Danish Neonatal Screening Biobank can be used for research after approval from the Biobank, and the relevant Scientific Ethical Committee. There is also a mechanism in place ensuring that one can opt out of having the stored material used for research. The Danish Data Protection Agency and the Danish Health Data Authority approved this study. According to Danish law, informed consent is not required for register-based studies. All data accessed were deidentified.

C3 and C4 protein concentrations

These methods have been described in a related study³⁵. Two 3.2 mm discs of DBS were punched into 96 well polymerase chain reaction plates (72.1981.202, Sarstedt). The extracts were analyzed with a multiplex immunoassay (also measuring vitamin D binding protein³⁵) using U-plex plates (Meso-Scale Diagnostics (MSD), Maryland, US) employing antibodies specific for complement C3 (HYB030-07 and HYB030-06) and complement C4 (MA1-72520 (ThermoFisher Scientific) and HYB162-04). The antibodies were purchased from SSI Antibodies (Copenhagen, Denmark) except if otherwise stated. Extracts were analyzed diluted 1:70 in diluent 101 (#R51AD, MSD). Capture antibodies (used at 10 μg/mL as input concentration) were biotinylated in-house using EZ-Link Sulfo-NHS-LC-Biotin (#21327, Thermo Fisher Scientific) and detection antibodies were SULFO-tagged

277 (R91AO, MSD), both at a challenge ratio of 20:1. As calibrators, we used complement components

278 purified from human: C3: #PSP-109 (Nordic Biosite, Copenhagen, DK), C4: abx060108 (Abbexa,

- $\,$ Cambridge, UK). Calibrators were diluted in diluent 101, detection antibodies (used at 1 $\mu g/mL)$ were
- diluted in diluent 3 (#R50AP, MSD). Controls were made in-house from part of the calibrator solution
- in one batch, aliquoted in portions for each plate, and stored at -20°C until use. The samples were
- prepared on the plates as recommended by the manufacturer and were read on the QuickPlex SQ
- 283 120 (MSD) 4 min after adding 2x Read buffer T (#R92TC, MSD). Analyte concentrations were
- 284 calculated from the calibrator curves on each plate using 4PL logistic regression using the MSD
- 285 Workbench software.

286 Intra-assay variations were calculated from 38 measurements analyzed on the same plate of a pool

- of extract made from 304 samples. Inter-assay variations were calculated from controls analyzed in
- duplicate on each plate during the sample analysis, 1022 plates in total. Lower limits of detections
- were calculated as 2.5 standard deviations from 40 replicate measurements of the zero calibrator.
- The higher detection limit was defined as the highest calibrator concentration. The lower and upper
- detection limits for: (a) C3 were 95.4 and 7.98×10^4 µg/L respectively, and (b) C4 were 55.2 and
- $7.98 \times 10^4 \, \mu g/L$ respectively. The intra- and inter-assay coefficient of variation (CV) for (a) C3 were
- 293 5.2% and 18.1% respectively; and for (b) C4 were 3.9% and 8.5% respectively. To validate the
- stability of the samples during storage, we randomly selected 15-16 samples from five years (1984,
- 295 1992, 2000, 2008, and 2016; a total of 76 samples). After extracting the samples and adding them to
- an MSD plate, the rest of the extracts were frozen for 2 months, thawed and measured as described
- above to imitate the freeze-thaw cycle of the samples in the study. The oldest samples (from 1984) recorded higher concentrations, most probably due to a change in the type of filter paper after
- 299 1989. In light of this artefact, we adjusted all DBP values by plate (the sequence of testing followed
- 300 the date of birth of the sample). This is described below. Additional details related to pre-analytic
- variation are provided in **Supplementary Methods 1.**

Imputation of genotypes

302

318

- 303 DNA genotyping was conducted at the Broad Institute (Boston, MA, USA) using the Infinium
- PsychChip v1.0 array (Illumina, San Diego, CA, USA)³⁶. We restricted the genotyped SNPs to 252,339
- 305 high quality, common SNPs based on build hg19 (the same human genome reference build was used
- throughout this study). Details of the filtering can be found elsewhere (Schork et al., 2019). Briefly,
- we excluded SNPs with minor allele frequency (MAF) < 0.01, Hardy Weinberg Equilibrium (HWE) p-
- 308 value < 1.0×10⁻⁶ or non-SNP alleles (i.e., insertions and deletions, INDELs). 245,328 autosomal and
- 309 7,011 X-chromosome (chrX) SNPs were retained and used to impute SNPs using the Ricopili
- 310 pipeline³⁷ with the Haplotype Reference Consortium (HRC)³⁸ as the imputation reference panel
- 311 (accession number: EGAD00001002729). 6,743,499 autosomal SNPs, 227,371 chrX SNPs for males
- and 184,517 chrX SNPs for females were retained with missing rate < 0.02 and genotype call
- 313 probability > 0.8. We further excluded the imputed SNPs with imputation info score < 0.8, MAF <
- 314 0.01 or HWE p-value $< 1.0 \times 10^{-6}$. 5,201,724 SNPs were retained in autosomes and 126,109 SNPs were
- retained on chrX. We then used the common SNPs to infer the genetic ancestries of 80,873
- participants in the iPSYCH2012 study, 75,764 individuals of European ancestry and 5,109 individuals
- of non-European ancestry. Details are provided in **Supplementary Method 2**.

Imputation of C4 haplotypes

- 319 C4 haplotypes were imputed from reference data^{9,14} using the genotyped SNPs in the iPSYCH2012
- 320 sample. The human C4 haplotypes have various copy numbers, including two isotypic
- 321 polymorphisms, C4A (A) and C4B (B). Each isotype has two length-polymorphisms due to a human
- 322 endogenous retroviral (HERV) insertion, long form (L, with HERV insertion) and short form (S,
- without HERV insertion). The isotypic and length polymorphisms lead to four alleles in a C4 copy, AL,
- 324 AS, BL and BS. Using the genotyped SNPs, the C4 haplotype reference was used to impute the C4

alleles and the number of C4 copies (with a maximum copy number of 4). The C4 haplotype imputation panel comprised whole genome sequencing data from 1,234 individuals of multiple ancestries, which enabled us to identify C4 alleles with high accuracy. We used Beagle software³⁹ for the imputation with the C4 haplotype reference. The imputation results provided the counts of alleles, but were unable to confidently distinguish all combinations of variants, for example, between the haplotypes AS-BL and AL-BS. We counted the two C4 alleles (C4A and C4B) with combination of HERV using a subset of the imputed result, where combinations can be confidently distinguished (details are provided in Supplementary Method 3). Both counts of C4 allele combinations and reported studies⁴⁰ indicated that the C4A gene is more likely to carry HERV insertion than the C4B gene. Therefore, the C4 haplotype is assumed to be AL-BS rather than AS-BL, consistent with methods described by Sekar et al9. The imputed counts were converted to the C4 haplotypes. Eight common C4 haplotypes (allele frequencies \geq 0.01) were imputed in the iPSYCH2012 study (Supplementary Table 3). The allele frequencies of the 8 haplotypes were consistent with other studies^{14,41}. Given the common *C4* haplotypes, we counted the copy numbers of the C4 alleles (Supplementary Figure 2) for each participant. 28 individuals (0.04%) carried 4 copies of C4B and 35 individuals (0.05%) carried 6 copies of HERV insertion. Therefore, we excluded these individuals with very rare copy numbers. The C4A copy number is strongly correlated with C4B and HERV copy numbers (Pearson correlation between C4A and C4B = -0.52; between C4A and HERV = 0.73).

Quality control of the C3 and C4 protein concentrations

The C3 and C4 protein concentrations were measured in 78,268 iPSYCH2012 participants of multiple ancestries. We focused on 68,768 individuals of European ancestry with measures of C3 and C4 protein concentrations. The protein assay plates captured a substantial amount of variance (C3 = 49.4%, C4 = 45.3%). Therefore, we used a linear mixed model (LMM)⁴² approach to adjust protein concentrations, $y = \sum z_{\text{plate}} u_{\text{plate}} + e$, where y represents the C3/4 protein concentration; z_{plate} represents protein assay plate, a random variable; u_{plate} represents the random effect of protein assay plate; and e represents residual. The mixed model regression was conducted by the R package of lme4 (Bates et al., 2015). The rank-based inverse normal transformation (RINT)⁴³ was applied to the residuals to have mean 0 and variance 1. The standard deviations (SDs) adjusted for variance captured by protein assay plate were used for the interpretation of results of C3 and C4 protein concentrations, for C3 protein concentration, 1 SD unit = 2.56 μ g/L (3.60 μ g/L × $\sqrt{(1 - 0.49)}$), and for C4 protein concentration, 1 SD unit = 2.46 μ g/L (3.33 μ g/L × $\sqrt{(1 - 0.45)}$).

Heritability and SNP-based heritability of the C3 and C4 protein concentrations

The iPSYCH2012 cohort had 75,764 participants of European ancestry. 19,113 participants who shared a genetic relatedness (entry of genetic relationship matrix, r_{GRM}) \geq 0.05 with at least one other individual were considered as relatives; 3,253 first degree ($r_{GRM} \geq$ 0.4), 2,077 second degree relatives (0.2 \leq r_{GRM} < 0.4) and 13,783 third degree relatives (0.05 \leq r_{GRM} < 0.2). We jointly estimated both the heritability (h^2) and the SNP-based h^2 (h^2_{SNP}) of the C3 and C4 protein concentrations by using the method proposed by Zaitlen et al⁴⁴. This method assumes a normal distribution of SNP effect sizes. The GWAS studies of protein concentrations⁴⁵⁻⁴⁷ observed that SNPs in or near the coding genes would capture more phenotypic variance than the remaining SNPs. Therefore, we used two approaches to further explore the h^2_{SNP} , 1) estimating it using all common SNPs by BayesR⁴⁸, which assumes a mixture distribution of SNP effect sizes and can be used to test number of SNPs with nil, small, median and large genetic variance (small R^2 < 0.01%, median 0.01% \leq R^2 < 0.1%, and large 0.1% \leq R^2 < 1%) in addition to estimation of h^2_{SNP} , and 2) partitioning h^2_{SNP} into (a) $h^2_{Cis-chr}$, explained by SNPs on the chromosome where the coding gene (cis-chr SNPs) was positioned, and (b)

- 371 $h^2_{\text{trans-chr}}$, explained by the remaining SNPs (trans-chr SNPs). To partition h^2_{SNP} , we divided SNPs into
- two subsets, 1) cis-chr and 2) trans-chr SNPs. The $h^2_{cis-chr}$ and $h^2_{trans-chr}$ were estimated by using GCTA-372
- 373 GREML⁴⁹ and BayesR. Only genetically unrelated participants were included in the two analyses. The
- 374 genetic relationship matrix used in the Zaitlen and GREML analyses were estimated from 5,201,724
- 375 common SNPs. Only the subset of HapMap phase 3 (HM3) SNPs were included in the BayesR
- 376 analyses because of the computation complexity (853,129 HM3 SNP in total; for C3 protein
- 377 concentration, 132,239 cis-chr SNPs and 839,891 trans-chr SNPs; for C4 protein concentration,
- 378 60,631 cis-SNPs and 792,498 trans-SNPs). The Zaitlen method and GREML were implemented in
- 379 Genome-wide Complex Trait Analysis (GCTA)⁵⁰. BayesR was implemented in Genome-wide Complex
- 380 Trait Bayesian analysis (GCTB). The URLs for these programs are provided below.
- We estimated the genetic correlation between C3 and C4 concentrations by BOLT-REML⁵¹. To further 381
- examine if the genetic correlation was primarily driven by the two protein-coding genes (i.e. C3 and 382
- 383 C4), we conducted the BOLT-REML and Haseman-Elston regression⁵² analyses using the trans-chr
- SNPs. The Haseman-Elston regression was implemented in GCTA. 384

GWAS of C3 and C4 protein concentrations

- We performed the GWAS analysis of the C3 and C4 protein concentrations by fastGWA⁵³. The 386
- fastGWA is a LMM method which can include all individuals of European ancestry regardless of 387
- 388 relatedness. 5,201,724 imputed SNPs were analysed in the GWAS. In addition, fastGWA can include
- candidate markers which optimizes power if particular SNPs capture a large proportion of the total 389
- 390 variance⁵⁴. Therefore, we excluded the SNPs in and near the coding gene for the required GRM in
- 391 the GWAS, C3: chr19, 4.67Mb - 8.74Mb, C4: chr6, 24.8Mb - 33.9Mb. For each GWAS, we fitted
- birthyear, sex, wave (i.e., genotyping batch) and the first 20 PCs as covariates in the model. The PCs 392
- 393 were estimated by FastPCA⁵⁵, excluding the same SNPs as we did for the required GRM. We
- 394 conducted the GWASs using all SNPs on autosomal and sex chromosomes. SNPs on X chromosome
- for males (coded as 0/2) were tested as diploid, assuming X chromosome of males has half dosage 395
- 396 compensation⁵⁶. We used GCTA-COJO⁵⁰ to identify the SNPs which were independently associated
- 397 with the two concentrations. We randomly sampled 10,000 participants from the population-based
- 398 sub-cohort of iPSYCH2012 as the LD reference cohort. The GWAS significance threshold was 5.0×10⁻¹
- 399

403

385

- 400 To explore if the enrichment of mental disorder cases in the iPSYCH2012 case-cohort could induce
- 401 bias within the GWASs, we conducted simulations with ascertained individuals and performed
- 402 GWASs in the population-based sub-cohort (Supplementary Method 4).

Associations between C4 haplotypes and protein concentrations

- We examined the associations between the imputed C4 haplotypes and the two observed C3 and C4 404
- 405 protein concentrations. We first examined the associations of C4 copy numbers using a LMM
- 406 approach, $y_{\text{protein}} = x_{\text{copy}}b_{\text{copy}} + \sum x_cb_c + \sum z_{\text{-MHC}}u_{\text{-MHC}} + e$, where y_{protein} was C3/4 protein concentration;
- 407 x_{copy} was copy number of C4 allele, either C4A, C4B or HERV; b_{copy} represents effect of copy number;
- x_c was covariate with b_c being its effect; Both b_{copy} and b_c were fixed effects. The covariates in the 408
- 409 model were the same as those fitted in the GWAS of C4 protein concentration. Because of the strong
- 410 linkage disequilibrium in the MHC region, fitting SNPs in the region is likely to underestimate the
- effects of C4 allele count and reduce power. Therefore, we fitted the SNPs outside the MHC region 411
- 412 (z_{-MHC}) in the model with u_{-MHC} being their random effects. In practice, the effect of copy number
- 413 from the linear mixed model could be estimated by generalized least squares (GLS) method, $b = (X^T V^T)^T$
- 414 ¹X)⁻¹X^TV⁻¹y_{protein}, where X = { x_{copy} , x_c } and V was phenotypic covariance matrix of C3/4 protein

415 concentration. It was implemented by GCTA-GREML. All the individuals of European ancestry were

416 included in the analysis. The three C4 allele counts were correlated. Therefore, we estimated the

- joint effects using the same LMM approach as above, $y_{\text{protein}} = x_{\text{C4A}}b_{\text{C4A}} + x_{\text{C4B}}b_{\text{C4B}} + x_{\text{HERV}}b_{\text{HERV}} + \sum x_c b_c + \sum x_c b_$
- 418 $\Sigma z_{-MHC}u_{-MHC} + e$. In the model, x_{C4A} , x_{C4B} and x_{HERV} represent respectively counts of C4A, C4B and HERV.
- The remaining variables were defined as above. Secondly, we further examined the associations of
- 420 the imputed C4 haplotypes using the LMM approach. Previous studies have reported a strong effect
- for the C4A gene⁹, while the effect of C4B remains unclear⁵⁷. Therefore, we used 'BS' as the
- 422 reference haplotype to estimate joint effects of the remaining haplotypes. The regression model can
- be expressed as, $y_{\text{protein}} = \sum x_{\text{allele}} b_{\text{allele}} + \sum x_c b_c + \sum z_{\text{-MHC}} u_{\text{-MHC}} + e$, where x_{allele} represents *C4* haplotype.
- Seven *C4* haplotypes were included in the model, except for BS. The remaining parameters were
- defined as above. The estimated effect can be interpreted as the effect of the C4 haplotype
- 426 compared to BS. All the European participants were included in the analysis. The significance
- 427 threshold for these analyses was the same as the main GWAS significance threshold (i.e., 5.0×10^{-8}).

FUMA and SMR

428

- 429 We conducted gene-based analysis by Functional Mapping and Annotation of Genome-Wide
- 430 Association Studies (FUMA)⁵⁸. There were 18,305 genes available for the gene-based analysis, thus
- the Bonferroni corrected threshold was 1.4×10^{-6} (= 0.05 / (18,305 × 2)). We conducted Summary-
- data-based Mendelian Randomisation (SMR)⁵⁹ to identify pleiotropic genes for C3 and C4
- 433 concentrations. For the SMR analysis, the eQTL data (i.e., summary statistics from associations of
- gene expressions), was Genotype-Tissue Expression version 8 (GTEx v8)⁶⁰. The LD reference sample
- with 10,000 participants was the same as the above GCTA-COJO analysis. 22,338 gene-tagged probes
- 436 within 49 tissues (200,144 probes in total) which had significant SNPs were included in the SMR
- analysis. The Bonferroni significance threshold was 1.2×10^{-6} (= 0.05 / (200,144 × 2)).

438 Associations between C4 haplotypes and mental disorders observed within the iPSYCH2012 case-

439 *cohort study*

- 440 Based on the associations with protein concentrations, we conducted the associations between C4
- haplotypes and 6 iPSYCH2012 disorders (SCZ, BIP, DEP, ASD, ADHD and AN). We used three
- approaches to examine the relationships, 1) associations with C4 allele counts, 2) associations with
- imputed C4 haplotypes, 3) associations with predicted C4 gene expression in the brain. Because the
- 444 iPSYCH2012 case-cohort study has person-level data on the age-at-first contact with psychiatric
- services, we were able to assess the risk of mental disorders within the more informative time-to-
- event framework, using Cox proportional hazards regression (Cox PH) to analyse the hazards of C4
- allele counts and haplotypes with respect to the mental disorder of interest. For C4 allele count, we
- examined the joint effects due to their correlations, $h(t) = h_0(t) \exp(x_{C4A}b_{C4A} + x_{C4B}b_{C4B} + x_{HERV}b_{HERV} +$
- 449 $\Sigma x_c b_c$). In the model, $h_0(t)$ represents the baseline hazard while h(t) represents the hazard at time t
- 450 between baseline and December 2016. The remaining variables were defined as above. For C4
- haplotypes, we examined the joint effects using the Cox PH model, $h(t) = h_0(t) \exp(\sum x_{\text{allele}} b_{\text{allele}} + t)$
- 452 $\Sigma x_c b_c$). All the variables were defined as above. In addition to C4 haplotypes, we used the predicted
- 453 C4A and C4B gene expressions as outlined in the post-mortem brain study of Sekar et al.⁹ The
- association was conducted with a Cox PH model, $h(t) = h_0(t) \exp(x_{C4A_predicted} b_{C4A_predicted} + x_{C4B_predicted})$
- 455 $b_{C4B \text{ predicted}} + \sum x_c b_c$, where $x_{C4A \text{ predicted}}$ and $x_{C4B \text{ predicted}}$ represent the predicted C4A and C4B gene
- expressions, respectively. We included only unrelated individuals of European ancestry in the three
- 457 analyses.
- In the time-to-event analysis, the cases were the diagnosed participants by December 2016, and the
- 459 non-cases are defined as the entire cohort excluding those individuals with the disorder of interest.

- 460 Therefore, we defined six psychiatric-disorder samples for the time-to-event analyses. The sample
- sizes for cases and non-cases are shown in **Supplementary Table 1**.
- 462 Associations between protein concentrations and mental disorders observed within the
- 463 iPSYCH2012 case-cohort study
- Based on the associations between C4 haplotypes and 1) the two protein concentrations (C3 and C4)
- and 2) six mental disorders, we explored the associations between C3 and C4 protein concentrations
- and mental disorders observed in the iPSYCH2012 case-cohort study, using Cox PH models. We first
- tested the marginal effects of two concentrations, using the model $h(t) = h_0(t) \exp(x_{\text{protein}} b_{\text{protein}} + t)$
- 468 $\Sigma x_c b_c$). The variables were defined as above. Due to the high correlation, we then fitted both
- 469 concentrations jointly, $h(t) = h_0(t) \exp(x_{C3 \text{ protein}} b_{C3 \text{ protein}} + x_{C4 \text{ protein}} b_{C4 \text{ protein}} + \sum x_c b_c)$, where $x_{C3 \text{ protein}}$
- and $x_{C4_protein}$ represent C3 and C4 concentration, respectively. $b_{C3_protein}$ and $b_{C4_protein}$, effects of two
- 471 protein concentrations, were fixed effects. In the three analyses, we included only unrelated
- individuals of European ancestry.

473

Mendelian Randomisation analysis based on summary statistics

- We explored the relationships between protein concentrations and mental and autoimmune
- disorders using the generalised summary-data-based Mendelian Randomisation (GSMR) method⁶¹.
- 476 Because of the possible link between C3 and C4 and brain function⁷, we also included two
- 477 neurodegenerative disorders—Alzheimer's disease, and amyotrophic lateral sclerosis in these
- analyses. Thus, there were 8 broadly-defined neuropsychiatric disorders (i.e., SCZ⁶², DEP⁶³, BIP⁶⁴,
- 479 ASD⁶⁵, ADHD⁶⁶, AN⁶⁷, Alzheimer's disease⁶⁸, amyotrophic lateral sclerosis⁶⁹), and 6 autoimmune
- disorders (i.e., multiple sclerosis⁷⁰, type-1 diabetes⁷¹, Crohn's disease⁷², ulcerative colitis⁷²,
- rheumatoid arthritis⁷³, systemic lupus erythematous⁷⁴). The GWAS summary statistics for these
- 482 disorders were publicly available (additional details provided in **Supplementary Table 19**).
- 483 Unfortunately, detailed GWAS summary statistics for Sjögren's syndrome were not available. The
- 484 GSMR method was implemented in GCTA. The GSMR method includes options to exclude potentially
- 485 pleotropic loci (HEIDI filtering). Similar to the methods for pleiotropy exclusion, it assumes fewer
- 486 pleiotropic SNPs than valid variants and MR estimates may fluctuate with the inclusion of those SNP
- outliers⁶¹. Given that a substantial proportion of the variance in C4 concentration was associated
- 488 with SNPs in the MHC region (including the C4 gene), genetic variants used in the GSMR analysis may
- be dominated by those positioned in or near the region. Therefore, the interpretation of results
- 490 based on the large effect loci within the MHC can be misleading. As a planned analyses, we ran the
- 491 GSMR method again based on summary statistics from the GWAS of C4 concentration adjusted for
- 492 COJO SNPs within MHC region (as a covariate). In addition, in the presence of bidirectional GSMR
- findings (i.e., evidence of both protein concentration impacting on phenotype of interest, and vice
- versa; forward and reverse direction respectively), symmetrical (i.e., equivalent) effect sizes may
- reflect the presence of pleiotropy. It is of note that effects of C3/4 protein concentration on these
- 496 mental and autoimmune disorders by GSMR were equivalent to log odds ratio (OR) from logistic
- regression if we have all the phenotypes in a cohort⁶¹. We, therefore, reported the logOR and 95% CI
- in the results. The effects of mental and autoimmune disorders on C3/4 protein concentration may
- 436 In the results. The effects of mental and autoimmune disorders on C5/4 protein concentration may
- be required to be transformed for better interpretation⁷⁵. However, we only used the reserve GSMR
- results to examine the presence of reverse causation and pleiotropy. Therefore, we reported the
- 501 GSMR estimates directly. The LD reference sample which included 10,000 participants was the same
- as for the GCTA-COJO analysis. We conducted both forward (from C3/4 concentration to disorder)
- and reverse (from disorder to C3/4 concentration) analyses. We set HEIDI-outlier threshold at 0.01
- to filter horizontal pleiotropy. The GSMR Bonferroni corrected significance threshold was 1.9×10^{-3} (=
- 505 $0.05/(2 \times 13)$).

PheWAS based on UK Biobank phenotypes

Based on the GSMR analysis results, we conducted phenome-wide association studies (PheWASs) to explore the relationships with disorder outcomes. The PheWASs were conducted in the UK Biobank (UKB) cohort⁷⁶, a large population cohort with 487,409 participants of multiple ancestries. The genotypes were imputed to the HRC³⁸ and UK10K⁷⁷ reference panels by the UKB group. The quality controls were described in detail elsewhere 78, including generic ancestry determination, quality controls of imputed SNPs, and estimation of principal components. In the study, we included 1,130,559 HM3 SNPs on autosomal chromosomes, with MAF \geq 0.01, HWE *P*-value \geq 1.0 ×10⁻⁶, because only effects of HM3 SNPs were predicted by BayesR. The genetic relationship matrix was estimated by GCTA. 347,769 unrelated participants of European ancestry were retained with genetic relationship < 0.05. In the PheWAS analysis, we included 1,148 UKB phenotypes, 1) 1,027 disorders which were classified by ICD-10 codes, 2) 51 anthropometric measurements and brain imaging traits, and 3) 70 infectious disease antigens. The quantitative traits were standardised by RINT to have mean 0 and variance 1. We then used the model to test the associations, for quantitative traits, y = $x_{\text{protein prs}}b_{\text{protein prs}} + \sum x_c b_c + e$, where y represents quantitative trait in UKB; $x_{\text{protein prs}}$ represents polygenic scores for neonatal C3 and C4 protein concentrations predicted by BayesR; xc represent the covariate variables including birth year, sex and 20 PCs. For dichotomous traits, logit(y) = $x_{\text{protein prs}}b_{\text{protein prs}} + \sum x_c b_c + e$, where y represents the dichotomous trait and definitions of the remaining variables were the same as above. In addition, we conducted the PheWAS analyses for males and females separately using the same approach. Polygenic scores were predicted using GWASs in both sexes. The Bonferroni corrected significance threshold was 7.3×10^{-6} (= 0.05 / (1148 × 3×2)).

RESULTS

508

509

510

511

512

513 514

515 516

517

518

519

520

521

522

523

524

525

526 527

528 529

530

531 532

533 534

535

536 537

538

539

540

541

542 543

544

545

546

547

548 549

550

551 552

553

554

555

556

557

The iPSYCH2012 study, a population-based case-cohort, was designed to study the genetic and environmental factors of 6 mental disorders (Supplementary Table 1), SCZ, BIP, DEP, ASD, ADHD and AN. The study included 80,873 individuals of multiple ancestries. 75,764 European individuals were retained by principal components (PCs) projection (Supplementary Figure 1). The following analyses in our study were based on the European individuals. We imputed C4 haplotypes using the reference data^{9,14}. The imputation process predicted the counts of three C4 alleles (C4A, C4B and HERV), but is not able to confidently distinguish all combinations. From the subset of imputation result without ambiguity, C4A allele is more likely to carry a HERV than C4B allele (~1.5 higher) while C4A allele is much less likely to not carry a HERV (Supplementary Table 2, for C4A, 0.2%, for C4B, 21.2%), which is consistent with previous studies⁴⁰. Based on that, eight common C4 haplotypes were imputed with allele frequency (AF) ≥ 0.01 (Supplementary Table 3). Their frequencies were respectively BS (12%), AL (4%), AL-BS (23%), AL-BL (43%), AL-BS-BS (2%), AL-AL (11%), AL-AL-BS (3%), and AL-AL-BL (2%), consistent with the published studies^{14,41}. We counted the copy numbers of the three types of C4 alleles (C4A, C4B and HERV, Supplementary Figure 2). The copy numbers (i.e., count) for the different types of C4 alleles were correlated. C4A count was negatively correlated with C4B count (r = -0.52, P-value < 1.0×10^{-100}). HERV count was positively correlated with C4A count (r = 0.73, P-value < 1.0×10^{-100}), but negatively correlated with C4B count (r = -0.17, P-value < 1.0×10^{-100}).

There were 68,768 participants of European ancestry with measures of C3 and C4 protein concentrations. The distributions of the observed neonatal C3 and C4 protein concentrations were right skewed, with mean, median, SD, and interquartile range being respectively 7.1, 6.7, 3.6, and 5.1 - 9.2 µg/L for C3 protein concentration, and 6.9, 6.5, 3.3 and 4.9 - 9.0 µg/L for C4 protein concentration (Supplementary Table 4). Significant differences were observed in the protein concentrations between males and females (C3 protein concentration: difference = -0.32, SE = 0.03, P-value = 6.5×10⁻³²; C4 protein concentration: difference = -0.30, SE = 0.03, P-value = 2.7×10⁻³³).

While the variance captured by sex was small ($R^2 = 0.19\%$ for C3 protein concentration and 0.20% for C4 protein concentration), we fitted sex as a covariate in the following analyses. To account for the influence of duration of storage (Supplementary Figure 3) and between-protein assay plate variation, we regressed the concentrations of the plates using a linear mixed model (LMM) approach. The residuals were standardised (mean 0, variance 1) using rank-based inverse normal transformation (RINT). After standardisation, the concentrations of C3 and C4 were positively correlated $r_P = 0.65$ (*P*-value < 1×10⁻¹⁰⁰, **Supplementary Figure 4**).

Heritability of C3 and C4 protein concentrations

558

559 560

561 562

563

564 565 566

567

568

569

570

571 572

573

574

575

576

577

578 579

580 581

582

583 584

585

586

587

588

589

590

591

592

593

594

595 596

597 598

599

600

601

602 603

604

605

606 607 The h^2 of C4 by Zaitlen's method⁴⁴ was 40% (SE = 0.03, *P*-value = 2.7×10⁻⁴⁴, **Supplementary Table 5**) while the h^2_{SNP} was 26% (SE = 0.006, P-value < 1.0×10⁻¹⁰⁰). For C3, h^2 was 21% (SE = 0.03, P-value = 1.1×10^{-11}) and the h^2_{SNP} was 4% (SE = 0.005, *P*-value = 3.2×10^{-14}). The high genetic variance of C4 concentration was confirmed by BayesR⁴⁸ — the h^2_{SNP} for C4 was 24% (SE = 0.004, *P*-value 1.0×10⁻¹⁰⁰ and 6% (SE = 0.005, P-value = 4.4×10^{-39}) for C3. Moreover, ~50 HM3 SNPs captured substantial genetic variance ($R^2 > 0.1\%$), for C3 protein concentration 39 SNPs and for C4 protein concentration 62 SNPs. The observation was consistent with our expectation that SNPs in or near the salient encoding genes would capture a substantial proportion of phenotypic variance for these two circulating proteins. Thus, we partitioned SNPs into two subsets; (a) those on the chromosome where the coding gene is located (cis-chr SNPs), and (b) those on the remaining chromosomes (trans-chr SNPs), and jointly estimating SNP-based h^2 at the two subsets of SNPs, SNP-based h^2 cis-chr and $h_{\text{trans-chr}}^2$, using GREML⁴⁹. For C4, $h_{\text{cis-chr}}^2 = 14\%$ (SE = 0.005, *P*-value < 1.0×10⁻¹⁰⁰) and $h_{\text{trans-chr}}^2 = 4\%$ (SE = 0.006, P-value = 9.4×10^{-13}). For C3, $h^2_{cis-chr}$ was 0.4% (SE = 0.001, P-value = 1.1×10^{-3}) and $h^2_{trans-chr}$ = 3% (SE = 0.006, P-value = 1.4×10⁻⁷). The cis-chr SNPs of C4 concentration captured more genetic variance than the trans-chr SNPs. A higher genetic variance was found at cis-chr SNPs by BayesR. For C4, $h_{cis-chr}^2 = 22\%$ (SE = 0.003, P-value < 1.0×10⁻¹⁰⁰) and $h_{trans-chr}^2 = 5\%$ (SE = 0.004, P-value = 6.2×10⁻³⁰). For C3, $h^2_{cis-chr} = 2\%$ (SE = 0.001, P-value = 3.9×10^{-80}) and $h^2_{trans-chr} = 5\%$ (SE = 0.004, P-value = 5.9×10^{-80}) ²⁶). Both the Zaitlen method and GREML assume genetic variance at each SNP follows a normal distribution while BayesR assumes a mixture distribution. The BayesR estimates are expected to better model the true underlying genetic architecture. We only used individual-level-data-based methods (such as Zaitlen's method, GREML and BayesR) in the analysis as genotypes and phenotypes were all available, since summary-level-data-based methods modelling LD from reference cohorts are less accurate. In summary, both C3 and C4 concentrations were heritable traits. SNPs positioned in the C4 gene accounted for a substantial proportion of the genetic variance of C4 concentration.

The genetic correlation (r_q) between the two concentrations based on BOLT-REML⁵¹ was 0.38 (Supplementary Table 6, SE = 0.03, P-value = 1.9×10^{-35}), smaller than the phenotypic correlation (0.65). Given the large genetic effects at the coding genes for C3 and C4 we then estimated $r_{\rm g}$ using SNPs other than chromosomes 6 or 19 (related to the location of C4 and C3 genes, respectively) to further investigate if the correlation was driven by cis-chr SNPs, $r_q = 0.82$ (SE = 0.05, P-value = 4.8×10^{-65}). The high correlation was confirmed by Haseman-Elston regression⁵² ($r_g = 0.78$, SE = 0.19, P-value = 4.1×10^{-5}), using trans-chr SNPs. These results indicated that C3 and C4 were genetically correlated, and this genetic correlation was not driven by SNPs in or near their respective encoding genes.

GWAS of C3 and C4 protein concentrations

We used fastGWA⁵³ to conduct the GWAS analysis based on 75,764 participants of European ancestry and 5,327,833 common SNPs, 5,201,724 in autosomes and 126,109 on the X chromosome (Figure 2). We conducted a GCTA-COJO⁷⁹ analysis to help identify putative independent SNPs. For C4 protein concentration, 34 autosomal SNPs were identified as genome-wide significant

(**Supplementary Table 7**), and all were autosomal. For C3 protein concentration, 14 significant SNPs were identified, again all were autosomal (**Supplementary Table 8**).




Figure 2 GWASs of neonatal C4 and C3 protein concentrations. a) unadjusted C4 protein concentration, b) C4 protein concentration adjusted for COJO SNPs in the MHC region (fitted as covariates in the regression model), c) unadjusted C3 protein concentration and d) C3 protein concentration adjusted for COJO SNPs on chromosome 19. The COJO SNPs fitted as covariates in GWAS of adjusted protein concentration (panels b and d) were identified from GCTA-COJO analysis of unadjusted protein concentration. The COJO SNPs were highlighted with red colour. The top-associated SNPs were annotated with their overlapped or nearest genes. The GWAS threshold was 5.0×10^{-8} .

Of the 34 SNPs significantly associated with C4 protein concentration, 30 (88.2%, 30/34) were found on chromosome 6. Of these 29 were in the MHC region and 27 (79.4%, 27/34) SNPs were positioned within 2Mb of the C4 gene (chr6, 31.9 Mb). These 27 SNPs explained 16.7% of phenotypic variance in C4 concentration, which is consistent with the estimated $h^2_{\text{cis-chr}}$. SNP rs113720465 (32,005,355bp, ~1Kb away from C4B-AS1 [32,000-32,004Kb]) had the largest effect size (the A allele was associated with an increase of 0.76 standard deviation units of C4 protein concentration), however SNP rs3117579 had the smallest P-value (within an exon of GPANK1). Given this large effect size, it is possible that SNPs in LD at $r^2 < 0.01$ (the COJO threshold of independence) could also be reported as genome-wide significant through correlation. Thus, we conducted a GWAS fitting the COJO SNPs in and near MHC region as fixed effects (Figure 2). We identified 8 significant loci by COJO, 6 of which were significant from GWAS of unadjusted C4 protein concentration. The 2 additional loci were on chromosomes 9 (rs6477754) and X (rs12012736). Interestingly, nearly all the 8 COJO SNPs were annotated to the genes biologically related to complement-related pathways (Supplementary Figure 5). For example, C4BPA (rs12057769) encodes a binding protein of C4. The IL6 gene (rs2066992) encodes a cytokine stimulated in response to infections and injuries. C1S (7.1Mb on chr12) and C1R (7.2Mb on chr12), the nearest genes of rs11064501, are the protein-coding genes of two C1 subcomponents.

With respect to C3 protein concentration, 7 COJO SNPs were positioned within 2Mb of the *C3* gene (chr19, 6.7Mb) — these loci explained 3% of phenotypic variance in C3 concentration. After fitting these 7 COJO SNPs as covariates, 8 significant COJO SNPs were identified (**Supplementary Figure 6**). We found a SNP within the *ABO* gene, which has recently been identified as a 'master regulator' of plasma protein concentration^{46,80}. The gene annotations of the remaining SNPs encode proteins which involve immune- and/or C3-related pathways: (a) *FCGR2B* (rs844), which encodes an inhibitory receptor for the Fc region of immunoglobulin gamma (lgG), (b) *CFH* (rs558103 and rs11580821) which encodes Complement Factor H, a key factor that inhibits the alternative pathway and the amplification loop downstream from C3, (c) *STK19* gene (rs114492815) which is close to the *C4A* gene, and (d) *FAM117A* (rs12949906), which has enhanced gene expressions in dendritic cells (i.e., antigen-presenting cells involved in the immune system⁸¹.

For both GWASs of C3 and C4 protein concentration, we found no evidence of potential ascertainment bias related to the enrichment of cases with mental disorders in the iPSYCH2012 case-cohort study (**Supplementary Method 4, Supplementary Figures 8-10**). Therefore, the following post-GWAS analyses were based on the results from the full iPSYCH2012 sample.

Associations between C4 haplotypes and C3/4 protein concentration

Both h^2_{SNP} and GWAS results indicated strong effects of the SNPs in the MHC region for both C4 and C3 protein concentrations. Due to the complex LD structure in this region, we used the imputed C4 haplotypes to investigate phenotypic associations of these genetic variants. We first examined the associations between the imputed C4 haplotypes with the observed C4 protein concentration, using an LMM approach. As expected, more copies of C4 allele (either C4A, C4B, with or without HERV) were strongly associated with higher C4 protein concentration (**Figure 3**). The C4A copy number

667

668

669 670

671

672673

674 675

676

677

678 679

680

681

682

683 684

685 686

687 688

689

690

691 692

693

694

695

696

697

698

699

700

701702703

704

705

706

 (b_{C4A}) had greater effect than C4B (b_{C4B}) and HERV (b_{HERV}) , $b_{C4A} = 0.3$ (Supplementary Table 9, SE = 0.01, P-value < 1.0×10⁻¹⁰⁰), $b_{C4B} = 0.2$ (SE = 0.01, P-value < 1.0×10⁻¹⁰⁰), and $b_{HERV} = 0.2$ (SE = 0.004, P-value < 1.0×10⁻¹⁰⁰) value $< 1.0 \times 10^{-100}$). The C4 copy numbers were correlated. Therefore, we fitted all 3 gene copy numbers in a regression model to estimate the joint effects. The C4A copy number had nearly identical effect to C4B copy number, $b_{C4A} = 0.6$ (SE = 0.01, P-value < 1.0×10⁻¹⁰⁰), $b_{C4B} = 0.6$ (SE = 0.01, P-value < 1.0×10⁻¹⁰⁰). The beta estimates associated with the *HERV* copy number was less than the comparable estimates for C4A and C4B, and was negatively associated with C4 protein concentration, $b_{\text{HERV}} = -0.08$ (SE = 0.005, *P*-value = 5.0×10⁻⁵¹). This may reflect the strong correlation with C4A (r = 0.73) and negative correlation with C4B (r = -0.17). The result suggested 1 more copy of C4A or C4B is likely to have 1.6 μ g/L (~0.6 × SD unit) higher C4 protein concentration given the same amount of *HERV*. We calculated the captured variance $(R^2 = s^2b^2)$ that were comparable between the C4 copy numbers. In the formula, s^2 was variance of C4 copy number, analogous to variance of allele count. Of interest, the s^2 of C4A count was greater than C4B count (Supplementary Table 3, s^2 = 0.55 for C4A and 0.31 for C4B). Therefore, C4A count had a larger contribution to C4 protein concentration than the C4B count ($R^2 = 23\%$ for C4A and 11% for C4B). In total, both counts captured 17.3% of variance in C4 protein concentration, accounting for the negative correlation between the two allele counts (r = -0.52). The captured genetic variance was in line with $h^2_{\text{cis-chr}}$, and the genetic variance at the MHC SNPs. In summary, the imputed counts of both C4A and C4B were associated with the observed C4 protein concentration and C4A count had a greater contribution than C4B count.




Figure 3 Plot of *C4* copy number versus C4 protein concentration. There were three C4 alleles, (a) *C4A*, (b) *C4B* and (c) *C4L/HERV*. The colours represent *C4* allele counts.

Based on the effects of C4 allele counts, we then examined the association between the commonly observed C4 haplotypes and C4 protein concentration. For this analysis, we used the BS haplotype as the reference category (because of [1] the positive association between C4 allele count and C4 protein concentration, and [2] the greater contribution of C4A count to C4 protein concentration). All the remaining 7 common haplotypes were associated with increased C4 protein concentration. Due to their higher frequencies, AL-BS and AL-BL haplotypes captured greater variance of C4 protein concentration (**Supplementary Table 10**, $R^2 = 7.6\%$ for AL-BS and AL-BL).

We then examined C3 protein concentration. In keeping with expectations, we did not identify any significant associations between either *C4* copy number or *C4* haplotype, versus C3 protein concentration. However, we found the *AL-BS* haplotype was nominally significantly associated with C3 protein concentration ($b_{AL-BS} = 0.23$, SE = 0.03, P-value = 5.4×10⁻³). From the GWAS of C3

concentration, there was a COJO SNP positioned within the MHC region (rs114492815). While this SNP was in very weak association with each of the C4 allele counts ($R^2 < 0.005$ for C4A count and C4B count, 0.01 for C4L/HERV count), there was a moderate association with AL-BS ($R^2 = 0.11$). Therefore, we ran the analysis again, fitting rs114492815 as an additional covariate. After this adjustment, none of the haplotypes were associated with the C3 concentration (Supplementary **Table 10**). In general, C3 concentration was independent of C4 alleles.

Functional mapping of GWAS

707

708 709

710

711

712

713 714

715

716

717

718

719

720

721

722 723

724

725

726

727

728

729

730

731 732

733

734 735

736

737 738

739

740

741

742

743

744

745 746

747

748

749 750 751

752

753 754

755

756 757 Having found the significant SNPs from the GWASs, we explored the genes associated with both concentrations. For C4 concentration, we identified 263 significant genes by Functional Mapping and Annotation of Genome-Wide association Studies (FUMA), 257 (98%) on chromosome 6 and five (2%) on the remaining chromosomes (Supplementary Table 11). These findings are consistent with the high LD between loci in the MHC region and the high gene density in this region. Some differentiation between genes was achieved by using SMR which integrates the trait associations with significant eQTL associations. For SMR, using the eQTL summary data GTEx version 8, we identified 56 pleiotropic genes, 55 on chromosome 6 and one on chromosome 1 (Supplementary Table 12). We noted that the number of identified genes by SMR was smaller than by FUMA. Many genes on chromosome 6 were significant on the SMR test but failed to pass HEIDI test (i.e., there was evidence of pleiotropy). This was because of the complex LD and likely multiple causal alleles. Interestingly, SMR analysis found that C4A, C4B and C4BPA were all significantly associated with neonatal C4 protein concentration. These are three of the major genes involved in regulation of C4 protein concentration. The genetic correlates of neonatal C4 protein concentration were associated with higher C4A gene expressions in 8 brain tissues, amygdala ($b_{XY} = 0.70$, SE = 0.11, P-value = 3.7×10^{-10}), anterior cingulate cortex ($b_{XY} = 0.74$, SE = 0.13, P-value = 6.8×10^{-9}), caudate basal ganglia $(b_{XY} = 0.70, SE = 0.09, P$ -value = 2.6×10⁻¹⁶), cerebella hemisphere $(b_{XY} = 0.44, SE = 0.05, P$ -value = 8.2×10^{-18}), brain cerebellum ($b_{XY} = 0.43$, SE = 0.04, P-value = 5.1×10^{-22}), hippocampus ($b_{XY} = 0.68$, SE = 0.10, *P*-value = 8.0×10^{-12}), hypothalamus ($b_{XY} = 0.79$, SE = 0.11, *P*-value = 4.4×10^{-12}), and putamen basal ganglia (b_{XY} = 0.76, SE = 0.12, *P*-value = 8.6×10⁻¹⁰). Except for cerebellar hemisphere and cerebellum, the effect sizes of these associations were comparable with a mean of $b_{XY} = 0.73$. Overall, the findings from FUMA and SMR indicate strong associations between genes in the MHC region and C4 protein concentration, and the C4A gene was likely to have causal effect on C4 protein concentration in brain tissues. Interestingly, these significant genes were enriched with the Kyoto Encyclopedia of Genes and Genomes (KEGG) gene-sets of systemic lupus erythematosus (SLE, Pvalue = 1.1×10^{-70}) and complement systems (*P*-value = 7.2×10^{-4}) (**Supplementary Figure 7**). For C3 protein concentration, we identified 19 genes by FUMA (Supplementary Table 13). Within this set of genes, the DXO gene (chr6: 31.9Mb), which is positioned close to rs114492815, a significant SNP from the C3 GWAS, passed both SMR and HEIDI (a test of pleiotropy) tests (Supplementary Table 14). All these genes by FUMA and SMR were enriched with KEGG gene-sets of SLE (*P*-value = 3.5×10^{-1} ⁶), leishmania infection (*P*-value = 5.0×10^{-6}), complement systems (*P*-value = 9.1×10^{-6}) and Fc gamma R-mediated phagocytosis (*P*-value = 9.5×10^{-4}) (**Supplementary Figure 7**). In general, the identified genes (especially those within MHC region) suggest an association between SLE and the complement systems.

Associations with mental disorders within the iPSYCH2012 case-cohort study


We did not identify significant associations between C4A, C4B, or HERV copy numbers (Supplementary Table 15 or C4-related haplotypes (Supplementary Table 16) and any of the six mental disorders. Based on the formula between imputed C4 haplotypes and observed C4 gene expression (i.e., RNA concentration) in post-mortem brain tissue⁹, we found no significant associations between these estimates and any of the 6 mental disorders (Supplementary Table 17). Importantly, we did not find any significant associations between observed neonatal C4 protein

concentration and any of the six mental disorders. In models that accounted for the strong correlation between C3 and C4 concentration, we found no significant association between C3 concentration and any of the six mental disorders. (Supplementary Table 18).

758

759

Cox PH regression within the iPSYCH2012 case-cohort study



Mendelian randomisation based on summary statistics




Figure 4 Association between *C4*-related measures and mental disorders, and GSMR analyses with mental disorders. There were 6 mental disorders in the analyses: SCZ, DEP, BIP, ASD, ADHD and AN. The results shown in the top row were from time-to-event analyses between mental disorders and C4-related genotypes and phenotypes, including a) *C4* allele counts, b) imputed *C4* haplotypes, c) predicted *C4* gene expressions and d) C3 and C4 protein concentrations. The analyses were conducted in the iPSYCH2012 cohort. The results from Mendelian randomisation analyses (conducted by GSMR) were shown in the bottom row. The GSMR analysis using GWAS summary statistics predicted relationships between C4 protein concentration and mental disorders, e) using genetic variants from GWAS of C4 protein concentration, f) using genetic variants from GWAS of C4 protein concentration. The Bonferroni corrected thresholds were provided in Methods. Bars represent 95% confidence interval. Significant results were highlighted with "*".

GSMR relationships with candidate neuropsychiatric and autoimmune disorders

We conducted Mendelian randomization analyses to examine relationships between the two protein concentrations (C3 and C4) and neuropsychiatric and autoimmune disorders (**Supplementary Table 19**). The results are shown in **Figures 4 and 5**. In the unadjusted analysis (i.e., all loci including the MHC region; with and without HEIDI filtering), higher C4 protein concentration was found to be associated with three mental disorders (**Figure 4 and Supplementary Figure 11**, SCZ, DEP, BIP). The odds ratios for these three findings were small (1.05 or less). We found that these GSMR results were strongly dependent on SNP instruments that were in and near the MHC region (e.g., for schizophrenia and bipolar disorder 126 out of 130 SNPs, and for major depression 103 out of 107 SNPs). These three findings did not persist in the analyses adjusted for the MHC region SNPs. Overall, these analyses do not lend weight to the hypothesis that C4 is causally related to the risk of the psychiatric disorders included in the analyses.

In contrast, we found strong, protective effects of C4 concentration for several autoimmune disorders. Higher C4 concentration was associated with lower risks of multiple sclerosis, type-1 diabetes, rheumatoid arthritis and systemic lupus erythematosus (Figure 5). The effects were very large, especially for type-1 diabetes (OR = 0.54, 95% confidence interval [CI] = 0.50 - 0.58, $N_{SNP} = 47$) and systemic lupus erythematosus (OR = 0.37, 95% CI = 0.34 - 0.42, N_{SNP} = 103) (Supplementary Table 20). We identified that higher C4 concentration increased the risk of Crohn's disease (OR = 1.26, 95% CI = 1.19 – 1.34, N_{SNP} = 86). The strong effect of neonatal C4 protein concentration on these disorders were not caused by reverse causation (Supplementary Table 21 and Supplementary Figure 12). After removing the pleiotropic SNPs, genetic variants associated with all autoimmune disorders (except for type-1 diabetes) were not associated with C4 protein concentration in the reverse GSMR analysis (from autoimmune disorder to neonatal C4 protein concentration). When we examined the relationships adjusted for the MHC region SNPs, the significant association with SLE persisted. The effect size was comparable to that found using unadjusted C4 GWAS (with adjustment, OR = 0.24, 95% CI = 0.12 – 0.47, N_{SNP} = 7; without adjustment, OR = 0.37, 95% CI = 0.34 – 0.42, N_{SNP} = 103). Overall, these findings further support the hypothesis that higher C4 protein concentration is causally related to a reduced risk of systemic lupus erythematosus—it is predicted that an increase of 2.46 μg/L (1 SD unit) of C4 concentration would be associated with a 76% reduced risk (1 - 0.24) of systemic lupus erythematosus.

Mendelian randomisation based on summary statistics




Figure 5 GSMR analyses of C4 protein concentration against autoimmune disorders. The top two panels showed the Mendelian randomisation results a) using genetic variants from GWAS of C4 protein concentration, b) using genetic variants from GWAS of C4 protein concentration adjusted for COJO SNPs in the MHC region. The Bonferroni corrected threshold was 1.8×10^{-3} . Bars in the top 2 panels represented 95% confidence interval. Significant results were highlighted with "*". The lower five panels show the effects of genetic variants for C4 protein concentration without adjustment against effects for five autoimmune disorders. Significant findings were identified for multiple sclerosis, Crohn's disease, type-1 diabetes, rheumatoid arthritis and systemic lupus erythematosus. The estimates in the panels (OR, standard error and *P*-value) were estimated from GSMR. Slope of dash line represented logOR. Bars in the bottom 5 panels represented standard errors of SNPs from GWAS. Potential pleiotropic SNPs were excluded.

We then explored the relationships between C3 concentration and neuropsychiatric and autoimmune disorders by bidirectional GSMR. Mindful that analyses based on fewer instruments may be underpowered to detect small effects, no significant associations were identified with pleiotropic SNPs removed (**Supplementary Table 20**). Our findings provide no support for the hypothesis that C3 protein concentration is related to the risk of the neuropsychiatric nor autoimmune disorders examined in this study.

C3 and C4 phenome-wide association studies in the UK Biobank

With respect to C4 concentration, the PheWAS study in the UK Biobank identified significant associations with 35 phenotypes (Supplementary Table 22 and Supplementary Figure 13). Many of these were related to autoimmunity. Of the top 8 disease associations ranked by P-value, higher C4 concentration was associated with a reduced risk of six disorders, two were associated with an increased risk. The top 8 were intestinal malabsorption (which includes coeliac disease; ICD10 = K90, OR = 0.54, 95% confidence interval [CI] = 0.53 - 0.56); thyrotoxicosis [hyperthyroidism] (ICD10 = E05, OR = 0.77, 95% CI = 0.75 - 0.79; hypothyroidism (ICD10= E03, OR = 0.92, 95% CI = 0.90 - 0.93); insulin-dependent diabetes mellitus (ICD10 = E10, OR = 0.80, 95% CIs = 0.78 - 0.83); sarcoidosis (ICD10 = D86; OR = 0.79, 95% CIs = 0.75 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.06 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.06 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.06 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.06 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.06 - 0.83); psoriasis (ICD10 = L40; OR = 1.08, 95% CIs = 1.08, 91.10); systemic lupus erythematosus (ICD10 = M32, OR = 0.74, 95% CI = 0.69 - 0.80) and ankylosing spondylitis (ICD10 = M45, OR = 1.22, 95% CIs = 1.16-1.28). We also found a significant result for multiple sclerosis (ICD-10 = G35, OR = 0.88, 95% CI = 0.84 - 0.92). The attenuated results for the autoimmune disorders that were included in GMSR may be related to the low prevalence of these disorders (and the smaller number of cases in the UKB). In addition to the disorders which met the Bonferroni-corrected *P*-value threshold (*P*-value < 7.3×10^{-6}), we note that Sjögren's syndrome (ICD10 = M35; OR = 0.95, 95% CI = 0.92 - 0.97) was nominally significant. There were no significant findings between C4 and any neuropsychiatric disorders (ICD10 F codes). No significant difference was found between males and females. Overall, these findings lend weight to the hypotheses that neonatal C4 protein concentration is (a) not associated with the risk of neuropsychiatric disorders, but (b) is associated with reduced risks of several autoimmune disorders. There were no significant associations between C3 and any of the 1,148 phenotypes, which was in line with our GSMR findings (Supplementary Table 23 and Supplementary Figure 14).

DISCUSSION

809

810

811

812

813 814

815

816

817

818

819

820

821

822

823824

825

826

827

828

829

830

831

832

833

834835

836

837 838

839

840

841

842843

844

845 846

847

848

849

850

851

852

853854

Our findings provide new insights into the genetic architecture of C3 and C4. Reassuringly, we found a robust association between C4-related haplotypes (including copy number) and neonatal C4 protein concentration. The C3 and C4 protein concentrations were phenotypically and genetically

correlated ($r_p = 0.65$, P-value < 1×10⁻¹⁰⁰; $r_g = 0.35$, P-value = 1.9×10⁻³⁵, using all SNPs; and $r_g = 0.78$, P-value = 1.9×10⁻³⁵, using all SNPs; and P-value = 1.9×10⁻³⁵, using all S 855 value = 4×10^{-5} using trans-chr SNPs). The C3 and C4 GWAS findings identified variants in genes that 856 857 encode important proteins within the inter-connected complement pathways. In contrast to a 858 previous study⁹, we found that neither a higher imputed C4 haplotype count nor a higher observed C4 protein concentration was associated with an increased risk of schizophrenia or any other mental 859 860 disorder diagnosed in later life. We did, however, find evidence from Mendelian randomization 861 studies that support the hypothesis that C4 protein concentration is associated with a range of 862 autoimmune disorders. In models that incorporate the correlation between C4 and C3 protein 863 concentrations, we found no association between C3 and an altered risk of any mental disorder nor 864 autoimmune disorder. This following discussion will focus on 5 key findings. 865 First, with respect to C4 protein concentration, we found a stronger contribution of the C4A count compared to the C4B count. In keeping with prior smaller studies 18,19, we confirmed that the copy 866 numbers of C4A and C4B were robustly positively associated with the concentration of the C4 867 protein (C4A count; b = 0.33, SE = 0.005, P-value < 1×10^{-100} : C4B count; b = 0.18, SE = 0.007, P-value < 868 1×10^{-100}). In joint analyses that accounted for the pattern of correlations between the different types 869 of C4 allele counts, the C4A count had twice the contribution to overall C4 concentration compared 870 871 with C4B count. 872 Second, the protein concentrations of C3 and C4, which are key components of the complement initiation pathways⁸², were highly heritable. Both pedigree- and SNP-based h^2 estimates (standard 873 874 error) were appreciable for C4 (0.40 (0.03) and 0.26 (0.006) respectively). The same estimates for C3 875 were smaller; 0.21 (0.03) and 0.04 (0.005) respectively. As expected, SNPs within and near the 876 respective coding genes (C4, C3) contributed to more than half of the genetic variance of their 877 related proteins. 878 Third, our sample sizes for C3 and C4 concentrations GWASs were nearly twenty times larger than 879 the only published GWAS for these proteins¹⁸. With respect to C4 protein concentration, our series of linked GWASs provide important information about the genetic correlates of C4 protein 880 881 concentration that lie outside of the MHC complex. In the GWAS, 30 quasi-independent hits were on 882 chromosome six, within the MHC region. Six additional loci were found on chromosomes 1, 7, 9, 12, 883 14 and X. We identified a locus on chromosome 1 within C4BPA, which encodes C4 binding protein 884 (closely involved in C4 protein regulation). The locus on chromosome 12 (rs11064501) is adjacent to 885 two genes that encode proteins involved in complement cascade initiation (C1s, C1R). Interestingly, 886 a locus (rs12012736) was identified on the X chromosome. This locus may be one of the factors that 887 contributed to the small sex differences found for the C3 and C4 protein concentrations and to the 888 known sex differences in the risk of autoimmune disorders⁸³. 889 With respect to C3 protein concentration, apart from loci within the C3 gene (seven quasi-890 independent loci within this gene on chromosome 19), we found a locus within FCGR2B (Fc gamma 891 receptor IIb), which encodes a receptor for the Fc region of immunoglobulin gamma complexes 892 (IgG). The IgG complex forms part of the machinery required for the phagocytosis of immune 893 complexes. One locus in the MHC complex was identified, which is adjacent to the C4A gene. In 894 keeping with the prior GWAS¹⁸, we identified two loci within CFH, the gene that encodes 895 complement factor H. This protein is involved in complement regulation and has been linked to 896 several disease phenotypes (most notably, with age-related macular degeneration)84. CHF 897 specifically regulates C3, which slows the downstream complement activation. We also found a locus 898 within ABO, which was identified as having associations with over 50 other protein concentrations^{46,80}, thus variants in this gene could directly or indirectly influence generic protein 899

metabolic pathways (e.g., upstream metabolic steps, downstream protein degradation and excretion). In summary, our study has highlighted how genetic variants within several components of the complement cascades (i.e., at the systems level) could influence the concentration of key circulation proteins such as C3 and C4. We have summarized these findings in **Figure 6**.

900

901

902

903

904

907

908 909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926 927




Figure 6 Summary of the results from GWASs of neonatal C3 and C4 protein concentrations displayed within the complement cascade. For significant loci identified from COJO, proteins encoded by annotated genes were highlighted with red colour.

Fourth, convergent evidence found no association between several C4-related measures and risk of SCZ. Our study measured C4 protein concentration in 68,768 neonates, an age more proximal to the period of brain development consistent with the impact of C4 expression and synaptic pruning^{6,24}. The strong association between C4-related copy number and measured C4 protein concentration, and the biologically-plausible loci/genes identified in the C3 and C4 GWASs lend weight to the validity of our measures. We found that none of the following variables were associated with an altered risk of SCZ: (a) observed neonatal C4 concentration, (b) copy numbers of either C4A, C4B, or HERV, (c) major C4-related haplotypes, nor (d) imputed brain C4A RNA expression. Furthermore, there were no associations between these C4-related variables and any of the other 5 iPSYCH target psychiatric disorders. We also note that the PheWAS study found no significant associations between the summary statistics of C4 protein concentration and the UK Biobank-measured brain volumes (n = 28,613). Reassuringly, we note that the SMR analyses identified (a) C4A gene expression was strongly linked to C4 protein concentration, and (b) higher C4 neonatal protein concentration was associated with increased C4A gene expression in brain tissue (including amygdala, anterior cingulate cortex, caudate basal ganglia, cerebellum, hippocampus, hypothalamus and putamen basal ganglia). These particular findings support the hypothesis that the loci we observed in the GWAS not only influence circulating C4 protein concentration (i.e., as measured in

928

929

930

931

932 933

934 935

936

937

938

939

940

941

942

943

944 945

946

947

948

949

950

951

952

953

954

955

956

957

958959

960

961

962

963 964

965

966

967 968

969

970

971

972

973

974

the neonatal dried blood spots), but may also influence the expression of the C4 gene in the brain. In summary, we found no evidence to support the hypothesis that C4-related variables were causally related to the risk of SCZ, nor the other mental disorders included in the iPSYCH case-cohort study. Our findings allow us to refine future directions for schizophrenia research. We note that the most strongly associated SNPs in the two most recent SCZ GWASes (rs1233578 [28,712,247bp]¹⁰ and rs140365013 [27,523,869bp] 62) are both over 3Mb upstream from the C4A gene (31,95 – 31.97Mb). There are 598 known genes^{87,88} (including 417 protein-coding genes) annotated between rs140365013 and the C4A transcription start site, so this region should provide fertile grounds for the generation of new candidate genes that might explain the top hits in recent SCZ GWASes. Fifth, we found convergent evidence linking higher C4 protein concentration and a reduced risk of several autoimmune disorders, and an increased risk for Crohn's disease. Based on Mendelian randomization analyses, there was robust evidence with respect to a lower risk of systemic lupus erythematous. The protective effect remained significant when we adjusted C4 concentration for MHC SNPs (from C4 with MHC SNPs to SLE: OR = 0.37, 95% CI = 0.34 - 0.42; from C4 adjusted for MHC SNPs to SLE: OR = 0.24, 95% CI = 0.12 - 0.47). Evidence also emerged for a lower risk of type-1 diabetes, multiple sclerosis, and rheumatoid arthritis. Reassuringly, the UKB-based PheWAS found variants associated with increased neonatal C4 protein concentration were associated with (a) reduced risks of a wide range of disorders (including coeliac disease, thyrotoxicosis, hypothyroidism, type 1 diabetes, sarcoidosis, SLE, nephrotic syndrome, and multiple sclerosis; Sjögren's syndrome. was nominally significant), and (b) increased risks of several disorders (including psoriasis, ankylosing spondylitis, iridocyclitis; Crohn's disease was nominally significant). Our findings are consistent with a meta-analysis based on 16 case-control studies, where low C4 gene copy number (<4) was associated with an increased risk of any type of autoimmune disorder, including systemic lupus erythematous¹⁵. A study based on large-scale genetic and transcriptomic datasets by Kim et al.¹⁷ suggested that C4A-related gene expression was not associated with risk of schizophrenia-related synaptic gene expression, but was associated with disorders including inflammatory bowel disease, rheumatoid arthritis, and lupus. Our findings support these conclusions. Recently, it was reported that variants in C4A and C4B, which were thought to increase the risk for SCZ, are protective for two autoimmune disorders (systemic lupus erythematosus, Sjögren's syndrome)¹⁴. We also observed that higher C4 protein concentration was associated with increased risks of several autoimmune disorders. The mechanisms of action underpinning the pattern of increased and decreased risk of different autoimmune disorders remain poorly understood^{87,88}. In summary, our findings provide convergent evidence to support the hypothesis that C4 protein concentration is associated with the risk of a range of autoimmune disorders. Many GWASs have found links between loci in the MHC region and risk of autoimmune disorders⁸⁹-⁹⁴. Until recently, this has been interpreted as a connection between HLA genes and autoimmune disease. Recently, Kamitaki et al. have shown that the link between the MHC locus and SLE and Sjögrens may be explained by C4A-C4B allelic variance¹⁴ within the MHC region, thus expanding on smaller studies linking low copy number of C4^{15,95} and C4A⁹⁶ with higher risk of systemic lupus erythematous. This raises the possibility that the correlation between the MHC region and the other above-mentioned autoimmune diseases are also explained by the C4A-C4B allelic variance. Bian et al. 41 observed strong linkage disequilibrium with HLA alleles and BS (one of the C4 alleles). Regardless of these speculations, we found no evidence of causal relationships between (a) C4 copy number and C4 haplotypes, (b) predicted C4A and C4B gene expressions, and (c) C4 protein concentration versus SCZ and a range of mental disorders. We identified pleiotropy between C4 concentration and three mental disorders (SCZ, DEP, BIP) from GSMR analyses. The complex linkage

disequilibrium between the C4 gene and other genes in MHC region (including HLA genes) suggests

that we should be cautious when interpreting genotype to phenotype associations for loci within the MHC region.

Strengths and Limitations of the study

Our study has several strengths. Our sample was nearly 20 times larger than the only other published GWAS of C3 and C4¹⁸. With respect to the hypothesis linking complement to brain development, our complement assays were collected from neonatal samples (versus adult samples). Because the onset of mental disorders such as SCZ is often in the second and third decade of life, our samples are unlikely to be impacted by reverse causation (e.g., smoking may be linked to complement gene expression in the brain¹⁷) and medication effects may impact on post-mortem gene expression studies⁹⁷. With respect to limitations, because our samples were based on neonatal C3 and C4 concentrations, it remains to be seen if the genetic correlates we identified are stable across the lifespan. Also, we used an antibody that has been demonstrated to measure total C4 (i.e., both C4A and C4B), thus we are unable to isolate the concentrations of the two isoforms. The C3 and C4 concentrations in our study were derived from circulating plasma proteins, whereas the concentration of these proteins may vary between organs/tissues and also in response to local tissue activation pathways.

The study by Sekar et al.⁹, which was based on C4 haplotypes imputed from 28,799 schizophrenia cases and 35,986 controls, found that the *AL-AL* haplotype was associated with an odds ratio of 1.27 compared with the *BS* allele (i.e. a 27% increased odds). Our study, based on 2,517 cases and 51,799 non-cases, and using a more informative imputation training set⁹, found no significant association for this comparison (HR = 1.14, 95% CI = 0.84 - 1.54; **Supplementary Table 16**)). Because the Sekar et al. study included more schizophrenia cases in their analyses, it is feasible that our study was underpowered to confidently detect an association between C4 haplotypes and SCZ⁹. However, we had access to the concentrations of protein product of these haplotypes from a very large sample size (n = 68,768), and thus we could estimate the variance of neonatal C4 protein concentration. Based on this observed variance, our study had 80% power to confidently detect a 25% increased risk of SCZ (OR = 1.25) by 2.46 μ g/L C4 protein concentration (1 standard deviation unit). Thus, our study had sufficient power to detect the effect size previously identified by Sekar et al.⁹.

Conclusions

Our study provides new insights into the genetic and phenotypic correlates of C3 and C4 protein concentration and helps unravel the contribution of different C4-related copy numbers and haplotypes to C4 protein concentration. Based on convergent evidence, we found no evidence to support an association between C4-related measures and risk of SCZ, nor other psychiatric disorders. Mindful of the pitfalls of linking genotypes with phenotypes within the MHC region, we encourage the research community to continue to actively explore additional candidate loci for schizophrenia within this region. In contrast to our findings regarding mental disorders, convergent evidence emerged supporting an association between C4 protein concentration and risk of autoimmune disorders.

1016	URLs
1017	PLINK2: https://www.cog-genomics.org/plink/2.0/
1018	GCTA: https://yanglab.westlake.edu.cn/software/gcta/#Overview/
1019	BayesR: https://cnsgenomics.com/software/gctb/#Overview/
1020	BOLT-REML: https://alkesgroup.broadinstitute.org/BOLT-LMM/BOLT-LMM_manual.html
1021	FUMA: https://fuma.ctglab.nl/
1022	SMR: https://yanglab.westlake.edu.cn/software/smr/
1023	GTEx version 8 (SMR format): https://yanglab.westlake.edu.cn/software/smr/#DataResource/
1024	Human Protein Atlas: https://www.proteinatlas.org/
1025	UCSC: https://genome.ucsc.edu/
1026	

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

10631064

1065

1066

1067

1068

Acknowledgements The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The cis-eQTL data of GTEx version 8 was summarized into SMR format. This research has been conducted using the data resource under the database of Genotypes and Phenotypes (dbGaP) study accession phs001992, and using the UK Biobank Resource under Application Number 12505. The authors thank GenomeDK and Aarhus University for providing computational resources and support that contributed to these research results. We thank Dr. Joana A. Revez for her insightful comments on BayesR and R tools. Availability of data and materials Owing to the sensitive nature of these data, individual level data can be accessed only through secure servers where download of individual level information is prohibited. Each scientific project must be approved before initiation, and approval is granted to a specific Danish research institution. International researchers may gain data access through collaboration with a Danish research institution. More information about getting access to the iPSYCH data can be obtained at https://ipsych.au.dk/about-ipsych/. The summary statistics from the GWAS for C3 and C4 and related analyses will be made available via the GWAS Catalogue https://www.ebi.ac.uk/gwas/ (Accession numbers to follow). **Funding** This study was supported by the Danish National Research Foundation, via a Niels Bohr Professorship to John McGrath. Bjarni Vilhjalmsson was also supported by a Lundbeck Foundation Fellowship (R335-2019-2339). This research was conducted using the Danish National Biobank resource, supported by the Novo Nordisk Foundation. The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIMH (1R01MH124851-01 to A.D.B.) and the Universities and University Hospitals of Aarhus and Copenhagen. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). The Anorexia Nervosa Genetics Initiative (ANGI) was an initiative of the Klarman Family Foundation. Genotyping of the Anorexia patients were funded by the Klarman Family Foundation. MEB was supported by the Independent Research Fund Denmark (grant number, 7025-00078B) and by an unrestricted grant from The Lundbeck Foundation (grant number, R268-2016-3925); JCD was supported by a grant from the Danish Council for Independent Research (grant number, 0134-00227B); AFM was supported by an ARC Future Fellowship (FT200100837); KLM was supported by grants from The Lundbeck Foundation and the Brain & Behavior Research Foundation; NRW was supported by NHMRC 1173790 and 1113400. CMB is supported by NIMH (R56MH129437; R01MH120170; R01MH124871; R01MH119084; R01MH118278; R01 MH124871); Brain and Behavior Research Foundation Distinguished Investigator Grant; Swedish Research Council (Vetenskapsrådet, award: 538-2013-8864); Lundbeck Foundation (Grant no. R276-2018-4581).

Disclosures CM Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Lundbeckfonden (grant recipient); Pearson (author, royalty recipient); Equip Health Inc. (Clinical Advisory Board); Other authors have nothing to disclose.

1069

1070

1071

1072

1074 1075 References 1076 Minton, K. Innate immunity: The inside story on complement activation. Nat Rev Immunol 1077 14, 61 (2014). https://doi.org:10.1038/nri3603 1078 2 Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. 1079 Complement System Part II: Role in Immunity. Front Immunol 6, 257 (2015). 1080 https://doi.org:10.3389/fimmu.2015.00257 1081 3 Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol 6, 262 (2015). 1082 1083 https://doi.org:10.3389/fimmu.2015.00262 1084 4 Reis, E. S., Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. New insights into the immune 1085 functions of complement. Nat Rev Immunol 19, 503-516 (2019). 1086 https://doi.org:10.1038/s41577-019-0168-x 1087 5 Magdalon, J. et al. Complement System in Brain Architecture and Neurodevelopmental 1088 Disorders. Front. Neurosci. 14, 23 (2020). https://doi.org:10.3389/fnins.2020.00023 1089 6 Stephan, A. H., Barres, B. A. & Stevens, B. The complement system: an unexpected role in 1090 synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369-389 (2012). 1091 https://doi.org:10.1146/annurev-neuro-061010-113810 1092 7 Presumey, J., Bialas, A. R. & Carroll, M. C. Complement System in Neural Synapse Elimination 1093 in Development and Disease. Adv. Immunol. 135, 53-79 (2017). 1094 https://doi.org:10.1016/bs.ai.2017.06.004 1095 8 Blanchong, C. A. et al. Genetic, structural and functional diversities of human complement 1096 components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol 1097 1, 365-392 (2001). https://doi.org:10.1016/s1567-5769(01)00019-4 1098 9 Sekar, A. et al. Schizophrenia risk from complex variation of complement component 4. Nature 530, 177-183 (2016). https://doi.org:10.1038/nature16549 1099 Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from 108 1100 10 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014). 1101 https://doi.org:10.1038/nature13595 1102 Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-1103 11 1104 derived models of synaptic pruning. Nat Neurosci 22, 374-385 (2019). 1105 https://doi.org:10.1038/s41593-018-0334-7 Yilmaz, M. et al. Overexpression of schizophrenia susceptibility factor human complement 1106 12 1107 C4A promotes excessive synaptic loss and behavioral changes in mice. Nat. Neurosci. 24, 214-224 (2021). https://doi.org:10.1038/s41593-020-00763-8 1108 1109 13 O'Connell, K. S. et al. Association between complement component 4A expression, cognitive 1110 performance and brain imaging measures in UK Biobank. Psychol. Med., 1-11 (2021). https://doi.org:10.1017/s0033291721000179 1111 1112 14 Kamitaki, N. et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582, 577-581 (2020). https://doi.org:10.1038/s41586-020-2277-x 1113 Li, N. et al. Association between C4, C4A, and C4B copy number variations and susceptibility 1114 15 1115 to autoimmune diseases: a meta-analysis. Sci. Rep. 7, 42628 (2017). 1116 https://doi.org:10.1038/srep42628 1117 16 Cross-Disorder Group of the Psychiatric Genomics, C. et al. Genetic relationship between five 1118 psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984-994 (2013). https://doi.org:10.1038/ng.2711 1119 1120 17 Kim, M. et al. Brain gene co-expression networks link complement signaling with convergent 1121 synaptic pathology in schizophrenia. Nat. Neurosci. 24, 799-809 (2021). 1122 https://doi.org:10.1038/s41593-021-00847-z

1123 1124	18	Yang, X. et al. Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects. <i>PLoS Genet.</i> 8 , e1002916 (2012).
1125		https://doi.org:10.1371/journal.pgen.1002916
1126	19	Yang, Y. et al. Diversity in intrinsic strengths of the human complement system: serum C4
1127		protein concentrations correlate with C4 gene size and polygenic variations, hemolytic
1128		activities, and body mass index. <i>J. Immunol.</i> 171 , 2734-2745 (2003).
1129		https://doi.org:10.4049/jimmunol.171.5.2734
1130	20	Hebert, L. A., Cosio, F. G. & Neff, J. C. Diagnostic significance of hypocomplementemia.
1131		Kidney Int. 39, 811-821 (1991). https://doi.org:10.1038/ki.1991.102
1132	21	Mongan, D. et al. Peripheral complement proteins in schizophrenia: A systematic review and
1133		meta-analysis of serological studies. Schizophr. Res. 222, 58-72 (2020).
1134		https://doi.org:10.1016/j.schres.2020.05.036
1135	22	Murray, R. M. & Lewis, S. W. Is schizophrenia a neurodevelopmental disorder? <i>Br. Med. J.</i>
1136		(Clin. Res. Ed) 295 , 681-682 (1987).
1137	23	Weinberger, D. R. Implications of normal brain development for the pathogenesis of
1138		schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987).
1139	24	Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-
1140		dependent manner. Neuron 74, 691-705 (2012).
1141		https://doi.org:10.1016/j.neuron.2012.03.026
1142	25	Cooper, J. D. et al. Schizophrenia-risk and urban birth are associated with proteomic changes
1143		in neonatal dried blood spots. <i>Transl Psychiatry</i> 7, 1290 (2017).
1144		https://doi.org:10.1038/s41398-017-0027-0
1145	26	Pedersen, C. B. et al. The iPSYCH2012 case-cohort sample: new directions for unravelling
1146		genetic and environmental architectures of severe mental disorders. Mol. Psychiatry 23, 6-
1147		14 (2018). https://doi.org:10.1038/mp.2017.196
1148	27	Bybjerg-Grauholm, J. et al. The iPSYCH2015 Case-Cohort sample: updated directions for
1149		unravelling genetic and environmental architectures of severe mental disorders. medRxiv,
1150		2020.2011.2030.20237768 (2020). https://doi.org:10.1101/2020.11.30.20237768
1151	28	Pendergrass, S. A. et al. The use of phenome-wide association studies (PheWAS) for
1152		exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet.
1153		Epidemiol. 35 , 410-422 (2011). https://doi.org:10.1002/gepi.20589
1154	29	Thornton, L. M. et al. The Anorexia Nervosa Genetics Initiative (ANGI): Overview and
1155		methods. Contemp. Clin. Trials 74 , 61-69 (2018). https://doi.org:10.1016/j.cct.2018.09.015
1156	30	Munk-Jorgensen, P. & Mortensen, P. B. The Danish Psychiatric Central Register. <i>Dan. Med.</i>
1157		Bull. 44, 82-84 (1997).
1158	31	Mors, O., Perto, G. P. & Mortensen, P. B. The Danish Psychiatric Central Research Register.
1159	22	Scand J Public Health 39 , 54-57 (2011). https://doi.org:10.1177/1403494810395825
1160	32	Borgan, O., Langholz, B., Samuelsen, S. O., Goldstein, L. & Pogoda, J. Exposure stratified case-
1161		cohort designs. Lifetime Data Anal 6, 39-58 (2000).
1162	22	https://doi.org:10.1023/a:1009661900674
1163	33	Norgaard-Pedersen, B. & Hougaard, D. M. Storage policies and use of the Danish Newborn
1164		Screening Biobank. <i>J. Inherit. Metab. Dis.</i> 30 , 530-536 (2007).
1165	24	https://doi.org:10.1007/s10545-007-0631-x
1166	34	Hollegaard, M. V. et al. Whole genome amplification and genetic analysis after extraction of
1167		proteins from dried blood spots. <i>Clin. Chem.</i> 53 , 1161-1162 (2007).
1168	25	https://doi.org:10.1373/clinchem.2006.082313
1169 1170	35	Albiñana, C. et al. Genetic correlates of vitamin D-binding protein and 25 hydroxyvitamin D in neonatal dried blood spots. medRxiv, 2022.2006.2008.22276164 (2022).
1170		https://doi.org:10.1101/2022.06.08.22276164
1171	36	Gunderson, K. L. <i>et al.</i> Whole-genome genotyping. <i>Methods Enzymol.</i> 410 , 359-376 (2006).
1172	30	https://doi.org:10.1016/S0076-6879(06)10017-8
11/3		111103.77 GOT OT EXTENSION OF OUT 2 (UU) 1 UU 1 7 O

1174	37	Lam, M. et al. RICOPILI: Rapid Imputation for COnsortias PlpeLine. Bioinformatics 36, 930-
1175		933 (2020), https://doi.org/10.1093/bjoinformatics/btz633

- 38 McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. 1176 Genet. 48, 1279-1283 (2016). https://doi.org:10.1038/ng.3643 1177
- 1178 39 Browning, B. L., Zhou, Y. & Browning, S. R. A One-Penny Imputed Genome from Next-1179 Generation Reference Panels. Am. J. Hum. Genet. 103, 338-348 (2018). https://doi.org:10.1016/j.ajhg.2018.07.015 1180
- 40 Wouters, D. et al. High-throughput analysis of the C4 polymorphism by a combination of 1181 1182 MLPA and isotype-specific ELISA's. Mol. Immunol. 46, 592-600 (2009). 1183 https://doi.org:10.1016/j.molimm.2008.07.028
- Bian, B., Couvy-Duchesne, B., Wray, N. R. & McRae, A. F. The role of critical immune genes in 1184 41 brain disorders: insights from neuroimaging immunogenetics. Brain Commun 4, fcac078 1185 (2022). https://doi.org:10.1093/braincomms/fcac078 1186
- 1187 42 Jiang, J. & Nguyen, T. in Linear and Generalized Linear Mixed Models and Their Applications 1188 1-61 (Springer New York, 2021).
- 43 Beasley, T. M., Erickson, S. & Allison, D. B. Rank-based inverse normal transformations are 1189 increasingly used, but are they merited? Behav Genet 39, 580-595 (2009). 1190 1191 https://doi.org:10.1007/s10519-009-9281-0
- Zaitlen, N. et al. Using extended genealogy to estimate components of heritability for 23 1192 44 1193 quantitative and dichotomous traits. PLoS Genet. 9, e1003520 (2013). 1194 https://doi.org:10.1371/journal.pgen.1003520
- 1195 45 Yang, C. et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins 1196 implicated in neurological disorders. Nat Neurosci 24, 1302-1312 (2021). https://doi.org:10.1038/s41593-021-00886-6 1197
- 1198 46 Pietzner, M. et al. Mapping the proteo-genomic convergence of human diseases. Science 374, eabj1541 (2021). https://doi.org:10.1126/science.abj1541 1199
- 1200 47 Gudjonsson, A. et al. A genome-wide association study of serum proteins reveals shared loci 1201 with common diseases. Nat Commun 13, 480 (2022). https://doi.org:10.1038/s41467-021-1202 27850-z
- 1203 48 Zeng, J. et al. Signatures of negative selection in the genetic architecture of human complex traits. Nat. Genet. 50, 746-753 (2018). https://doi.org:10.1038/s41588-018-0101-4 1204
- 49 Yang, J. et al. Common SNPs explain a large proportion of the heritability for human height. 1205 Nat. Genet. 42, 565-569 (2010). https://doi.org:ng.608 [pii] 1206
- 1207 10.1038/ng.608
- 1208 50 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex 1209 trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011). https://doi.org:10.1016/j.ajhg.2010.11.011 1210
- 1211 51 Loh, P. R. et al. Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis. Nat. Genet. 47, 1385-1392 (2015). 1212 1213 https://doi.org:10.1038/ng.3431
- 1214 52 Elston, R. C., Buxbaum, S., Jacobs, K. B. & Olson, J. M. Haseman and Elston revisited. Genet 1215 Epidemiol 19, 1-17 (2000). https://doi.org:10.1002/1098-2272(200007)19:1<1::AID-1216 GEPI1>3.0.CO;2-E
- 1217 53 Jiang, L. et al. A resource-efficient tool for mixed model association analysis of large-scale data. Nat. Genet. 51, 1749-1755 (2019). https://doi.org:10.1038/s41588-019-0530-8 1218
- 1219 54 Yang, J., Zaitlen, N. A., Goddard, M. E., Visscher, P. M. & Price, A. L. Advantages and pitfalls in 1220 the application of mixed-model association methods. Nat Genet 46, 100-106 (2014). 1221 https://doi.org:10.1038/ng.2876
- Galinsky, K. J. et al. Fast Principal-Component Analysis Reveals Convergent Evolution of 1222 55 1223 ADH1B in Europe and East Asia. Am. J. Hum. Genet. 98, 456-472 (2016).
- https://doi.org:10.1016/j.ajhg.2015.12.022 1224

1225	56	Sidorenko, J. et al. The effect of X-linked dosage compensation on complex trait variation.
1226	50	Nat Commun 10, 3009 (2019). https://doi.org:10.1038/s41467-019-10598-y
1227	57	Woo, J. J., Pouget, J. G., Zai, C. C. & Kennedy, J. L. The complement system in schizophrenia:
1228		where are we now and what's next? <i>Mol. Psychiatry</i> 25 , 114-130 (2020).
1229		https://doi.org:10.1038/s41380-019-0479-0
1230	58	Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
1231		annotation of genetic associations with FUMA. Nat Commun 8, 1826 (2017).
1232		https://doi.org:10.1038/s41467-017-01261-5
1233	59	Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex
1234		trait gene targets. Nat. Genet. 48, 481-487 (2016). https://doi.org:10.1038/ng.3538
1235	60	GTEx Consortium. Genetic effects on gene expression across human tissues. <i>Nature</i> 550 , 204
1236		(2017). https://doi.org:10.1038/nature24277
1237	https:	://www.nature.com/articles/nature24277#supplementary-information
1238	61	Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from
1239		GWAS summary data. Nat Commun 9, 224 (2018). https://doi.org:10.1038/s41467-017-
1240		<u>02317-2</u>
1241	62	Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in
1242		schizophrenia. <i>Nature</i> 604 , 502-508 (2022). https://doi.org:10.1038/s41586-022-04434-5
1243	63	Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent
1244		variants and highlights the importance of the prefrontal brain regions. Nat. Neurosci. 22,
1245		343-352 (2019). https://doi.org:10.1038/s41593-018-0326-7
1246	64	Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases
1247		provides new insights into the underlying biology. <i>Nat. Genet.</i> 53 , 817-829 (2021).
1248	C.E.	https://doi.org:10.1038/s41588-021-00857-4
1249	65	Grove, J. et al. Identification of common genetic risk variants for autism spectrum disorder.
1250	66	Nat. Genet. 51 , 431-444 (2019). https://doi.org:10.1038/s41588-019-0344-8 Demontis, D. et al. Discovery of the first genome-wide significant risk loci for attention
1251 1252	66	deficit/hyperactivity disorder. <i>Nat. Genet.</i> 51 , 63-75 (2019). https://doi.org:10.1038/s41588-
1252		018-0269-7
1254	67	Watson, H. J. et al. Genome-wide association study identifies eight risk loci and implicates
1255	07	metabo-psychiatric origins for anorexia nervosa. <i>Nat Genet</i> 51 , 1207-1214 (2019).
1256		https://doi.org:10.1038/s41588-019-0439-2
1257	68	Marioni, R. E. et al. GWAS on family history of Alzheimer's disease. <i>Transl Psychiatry</i> 8 , 99
1258		(2018). https://doi.org:10.1038/s41398-018-0150-6
1259	69	van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic lateral
1260		sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.
1261		Nat. Genet. 53 , 1636-1648 (2021). https://doi.org:10.1038/s41588-021-00973-1
1262	70	International Multiple Sclerosis Genetics, C. Multiple sclerosis genomic map implicates
1263		peripheral immune cells and microglia in susceptibility. Science 365 (2019).
1264		https://doi.org:10.1126/science.aav7188
1265	71	Chiou, J. et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics.
1266		Nature 594 , 398-402 (2021). https://doi.org:10.1038/s41586-021-03552-w
1267	72	de Lange, K. M. et al. Genome-wide association study implicates immune activation of
1268		multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256-261 (2017).
1269		https://doi.org:10.1038/ng.3760
4070		

- 1270 73 Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. 1271 Nature **506**, 376-381 (2014). https://doi.org:10.1038/nature12873
- Julia, A. et al. Genome-wide association study meta-analysis identifies five new loci for 1272 74 1273 systemic lupus erythematosus. Arthritis Res. Ther. 20, 100 (2018).
- https://doi.org:10.1186/s13075-018-1604-1 1274

1275	75	Byrne, E. M. et al. Conditional GWAS analysis to identify disorder-specific SNPs for
1276		psychiatric disorders. <i>Mol Psychiatry</i> 26 , 2070-2081 (2021). https://doi.org:10.1038/s41380-
1277		<u>020-0705-9</u>
1278	76	Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide
1279		range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
1280		https://doi.org:10.1371/journal.pmed.1001779
1281	77	Consortium, U. K. et al. The UK10K project identifies rare variants in health and disease.
1282		Nature 526 , 82-90 (2015). https://doi.org:10.1038/nature14962
1283	78	Revez, J. A. <i>et al.</i> Genome-wide association study identifies 143 loci associated with 25
1284	, •	hydroxyvitamin D concentration. <i>Nat Commun</i> 11 , 1647 (2020).
1285		https://doi.org:10.1038/s41467-020-15421-7
1286	79	Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics
1287	75	identifies additional variants influencing complex traits. <i>Nat. Genet.</i> 44 , 369-375, S361-363
1288		•
	90	(2012). https://doi.org:10.1038/ng.2213
1289	80	Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and
1290	04	disease. <i>Nat. Genet.</i> 53 , 1712-1721 (2021). https://doi.org/10.1038/s41588-021-00978-w
1291	81	Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci Adv 7 (2021).
1292		https://doi.org:10.1126/sciadv.abh2169
1293	82	Dunkelberger, J. R. & Song, W. C. Complement and its role in innate and adaptive immune
1294		responses. Cell Res. 20, 34-50 (2010). https://doi.org:10.1038/cr.2009.139
1295	83	Schurz, H. et al. The X chromosome and sex-specific effects in infectious disease
1296		susceptibility. Hum Genomics 13, 2 (2019). https://doi.org:10.1186/s40246-018-0185-z
1297	84	Poppelaars, F. et al. A Family Affair: Addressing the Challenges of Factor H and the Related
1298		Proteins. Front. Immunol. 12, 660194 (2021). https://doi.org:10.3389/fimmu.2021.660194
1299	85	Kent, W. J. et al. The human genome browser at UCSC. Genome Res 12, 996-1006 (2002).
1300		https://doi.org:10.1101/gr.229102
1301	86	Lee, B. T. et al. The UCSC Genome Browser database: 2022 update. Nucleic Acids Res 50,
1302		D1115-D1122 (2022). https://doi.org:10.1093/nar/gkab959
1303	87	Jain, U., Otley, A. R., Van Limbergen, J. & Stadnyk, A. W. The complement system in
1304		inflammatory bowel disease. Inflamm Bowel Dis 20, 1628-1637 (2014).
1305		https://doi.org:10.1097/MIB.000000000000056
1306	88	Cleynen, I. et al. Genome-Wide Copy Number Variation Scan Identifies Complement
1307		Component C4 as Novel Susceptibility Gene for Crohn's Disease. Inflamm. Bowel Dis. 22,
1308		505-515 (2016). https://doi.org:10.1097/MIB.00000000000000623
1309	89	Cruz-Tapias, P., Rojas-Villarraga, A., Maier-Moore, S. & Anaya, J. M. HLA and Sjogren's
1310		syndrome susceptibility. A meta-analysis of worldwide studies. <i>Autoimmun Rev</i> 11 , 281-287
1311		(2012). https://doi.org:10.1016/j.autrev.2011.10.002
1312	90	Hanscombe, K. B. <i>et al.</i> Genetic fine mapping of systemic lupus erythematosus MHC
1313	30	associations in Europeans and African Americans. <i>Hum Mol Genet</i> 27 , 3813-3824 (2018).
1314		https://doi.org:10.1093/hmg/ddy280
1315	91	International, M. H. C. <i>et al.</i> Mapping of multiple susceptibility variants within the MHC
1316	91	region for 7 immune-mediated diseases. <i>Proc Natl Acad Sci U S A</i> 106 , 18680-18685 (2009).
1317		https://doi.org:10.1073/pnas.0909307106
	02	
1318	92	Langefeld, C. D. et al. Transancestral mapping and genetic load in systemic lupus
1319	0.2	erythematosus. <i>Nat Commun</i> 8 , 16021 (2017). https://doi.org:10.1038/ncomms16021
1320	93	Li, Y. R. <i>et al.</i> Meta-analysis of shared genetic architecture across ten pediatric autoimmune
1321	0.4	diseases. <i>Nat Med</i> 21 , 1018-1027 (2015). https://doi.org:10.1038/nm.3933
1322	94	Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes.
1323	~ =	Nat. Genet. 53 , 1415-1424 (2021). https://doi.org:10.1038/s41588-021-00931-x
1324	95	Wu, Y. L. et al. Phenotypes, genotypes and disease susceptibility associated with gene copy
1325		number variations: complement C4 CNVs in European American healthy subjects and those

1326		with systemic lupus erythematosus. <i>Cytogenet Genome Res</i> 123 , 131-141 (2008).
1327		https://doi.org:10.1159/000184700
1328	96	Tsang, A. S. M. W. P. et al. Comprehensive approach to study complement C4 in systemic
1329		lupus erythematosus: Gene polymorphisms, protein levels and functional activity. Mol
1330		Immunol 92, 125-131 (2017). https://doi.org:10.1016/j.molimm.2017.10.004
1331	97	Hoffman, G. E. et al. Comment on: What genes are differentially expressed in individuals
1332		with schizophrenia? A systematic review. Mol Psychiatry (2022).
1333		https://doi.org:10.1038/s41380-022-01781-7
1334		